CN1904072A - Gene composition for screening pancreatic catheter gland cancer and its application - Google Patents
Gene composition for screening pancreatic catheter gland cancer and its application Download PDFInfo
- Publication number
- CN1904072A CN1904072A CN 200610052679 CN200610052679A CN1904072A CN 1904072 A CN1904072 A CN 1904072A CN 200610052679 CN200610052679 CN 200610052679 CN 200610052679 A CN200610052679 A CN 200610052679A CN 1904072 A CN1904072 A CN 1904072A
- Authority
- CN
- China
- Prior art keywords
- pancreas
- genes
- expression
- gene
- carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 62
- 238000012216 screening Methods 0.000 title claims abstract description 17
- 206010028980 Neoplasm Diseases 0.000 title description 14
- 201000011510 cancer Diseases 0.000 title description 5
- 210000004907 gland Anatomy 0.000 title 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims abstract description 90
- 206010073364 Ductal adenocarcinoma of pancreas Diseases 0.000 claims abstract description 11
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims abstract description 11
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract 4
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 62
- 230000014509 gene expression Effects 0.000 claims description 53
- 230000002068 genetic effect Effects 0.000 claims description 11
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 238000001514 detection method Methods 0.000 abstract description 2
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 115
- 238000012549 training Methods 0.000 description 55
- 238000002790 cross-validation Methods 0.000 description 53
- 238000001367 Mood's median test Methods 0.000 description 49
- 238000012360 testing method Methods 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 101150072531 10 gene Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention provides a group of assortment of genes, including 10 genes; L48784, X83300, A1620827, A1494291, NM-020970, BF433657, JO2959, BC 022313, NM-000904 and NM-004994, for screening ductal adenocarcinoma of pancreas. Said invention can utilize detection of said group of genes of human peripheral blood mononuclear cell to screen out patient with pancreatic cancer from health human group.
Description
Technology neck city
The invention belongs to biotechnology, relate generally to one group of assortment of genes, be used to screen ductal adenocarcinoma of pancreas.
Background technology
Carcinoma of the pancreas is the very poor malignant tumour of prognosis.Overall median survival time was less than 6 months.Survival rate had only 0.4-5% in 5 years.The surgical excision tumour can improve lifetime, and the patient's of ocal resection median survival time can reach 11-20 month, and survival rate can reach 7-25% in 5 years.But because the carcinoma of the pancreas patient lacks early stage clinical manifestation.When going to a doctor, patient how to have belonged to late period.
Because the operation risk of carcinoma of the pancreas excision and biopsy is bigger, so carcinoma of the pancreas clinical samples and be not easy to obtain, this just makes most of carcinoma of the pancreas patient can not get clear and definite and diagnoses timely, thereby has incured loss through delay patient's treatment.Therefore,, thereby reach the purpose of diagnosing tumour, will instruct our clinical position well if can from carcinoma of the pancreas patient's PBMC, find the relevant gene of tumour.
At present, CA199 is the pancreatic tumour mark of normal use.Research about CA199 is a lot of.Most research results thinks that the susceptibility of CA199 is about 80%, and specificity is present getable best pancreatic tumour mark about 60-70%.CA199 raises also can occur in other malignants tumor of digestive tract, as cancer of the stomach, colorectal carcinoma, biliary system malignant tumour; Also can occur in benign lesion, as pancreatitis, hepatitis and liver cirrhosis etc.
At present also do not have ideal to come the pancreatic tumour mark of autoblood, seek the tumor markers in the better carcinoma of the pancreas patient blood, have very high clinical value.
Summary of the invention
The purpose of this invention is to provide the assortment of genes of one group of screening ductal adenocarcinoma of pancreas, comprise 10 gene: L48784, X83300, AI620827, AI494291, NM_020970, BF433657, J02959, BC022313, NM_000904, NM_004994.
Another object of the present invention provides the application of this assortment of genes in the screening ductal adenocarcinoma of pancreas.
The present invention can filter out the carcinoma of the pancreas patient by detecting this group gene of human peripheral blood mononuclear cell from healthy population, specifically screen step and be:
1. according to Affymetrix chip gene expression profile operational guidance, use AFFYMETRIXHUMAN GENOME U133 PLUS 2.0 ARRAY to detect this expression of group gene in 5 carcinoma of the pancreas and 5 normal peoples' peripheral blood mononuclear cell (PBMC), obtain the signal value of genetic expression;
2.5 the average signal value of name carcinoma of the pancreas patient's peripheral blood mononuclear cell (PBMC) is higher than 5 normal peoples' gene and is considered to the up-regulated expression gene; The gene that the average signal value of 5 carcinoma of the pancreas is lower than 5 normal peoples is considered to reduce expressing gene;
3. the median of getting genetic expression signal value in above-mentioned 10 peripheral blood mononuclear cell is as threshold value, is to raise or downward modulation is expressed with the genetic expression of the PBMC that judges tested person; The people's of tested person PBMC, the expression trend that has the expression conditions more than 7 or 7 to raise in carcinoma of the pancreas PBMC or reduce with these genes in 10 genes is consistent, and just infers the artificial carcinoma of the pancreas patient of tested person; If in the people's of tested person PBMC, in 10 genes, the expression trend that has expression conditions more than 7 or 7 and these genes to raise in carcinoma of the pancreas or reduce does not meet, and the people who just infers tested person is the normal people.
The present invention utilizes the chip gene expression profile of Affymetrix company to carcinoma of the pancreas patient peripheral blood mononuclear cell (PBMC, peripheral blood mononuclear cells) express spectra and normal people's peripheral blood mononuclear cell express spectra are studied, the tumor-related gene of screening carcinoma of the pancreas is for the clinical diagnosis of carcinoma of the pancreas and screening provide new approach.Proved that in the experiment of small sample this experiment has very high susceptibility and specificity.Usefulness of the present invention is: (1) patients'blood is the sample that obtains easily; (2) screening method of the present invention is a kind of harmless detection method; (3) small sample high throughput oligonucleotide chip of expression spectrum has proved that this assortment of genes has very high supposition accuracy (100%).
Embodiment
The present invention is further described by embodiment.
Embodiment 1
1. according to Affymetrix chip gene expression profile operational guidance, use AFFYMETRIXHUMAN GENOME U133 PLUS 2.0 ARRAY to detect this expression of group gene in 5 carcinoma of the pancreas and 5 normal peoples' PBMC, obtain the signal value of genetic expression, (referring to table 1).
Table 1
| Sample | LA8784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 |
| T1 T2 T3 T4 T5 N1 N2 N3 N4 N5 | 6615.2 11386.6 5944.1 5007.4 6973.1 21113.1 10817.5 13886.1 16847.6 17733.3 | 340.3 658.7 496.2 453.5 703.5 773 782.5 1022.6 1836.3 1396.6 | 657.9 730.5 1018.2 890.8 1478.2 2161.5 1772.8 1846.8 2274.3 1949.2 | 708.1 553.5 698.7 484.8 673.4 919.2 1117.8 1752.5 1455 1110 | 508.6 963.8 522.8 745.3 642.2 1460.3 1194.4 1253.1 1472.4 1367.2 | 4103.5 2495.1 3439.2 3504.5 2453.1 1374.7 2041.6 1114.9 1231.2 1311.9 | 7571.2 10854.5 6894.9 10304.2 8012.7 5454.1 3179.9 2481.6 3431.4 2819.9 | 3893.3 4182.7 3176.2 5365.8 2728.2 1524 1808 1132.9 1102 1757.6 | 4635.3 1516.9 5390.5 4523.9 2784.2 1137 1649.9 1678.9 1497.5 770.6 | 10756.1 4475.7 7375.7 4207.6 3860.3 2043.6 2940 1351.5 1300.5 2171.3 |
| Median T mean N difference in means 2 | 11102.05 7327.8 17395.03 -10067.23 | 738.25 577.975 1257.125 -679.15 | 1625.5 1029.425 2057.95 -1028.525 | 813.65 602.6 1309.175 -706.575 | 1079.1 676.54 1349.48 -672.94 | 2247.35 2972.975 1258.175 1714.8 | 6174.5 9016.575 3546.75 5469.825 | 2268.1 3863.225 1379.125 2484.1 | 1664.4 3553.875 1271 2282.875 | 3400.15 4979.825 1716.725 3263.1 |
| Expression trend | Downward modulation | Downward modulation | Downward modulation | Downward modulation | Downward modulation | Raise | Raise | Raise | Raise | Raise |
The sample packet situation:
Carcinoma of the pancreas group: T1, T2, T3, T4, T5; Normal people's group: N1, N2, N3, N4, N5,
Public ID: public number of gene,
The T mean: the mean value of tumor sample signal value,
The N mean: the mean value of normal control sample signal value,
Difference 2=T mean-N mean differs from 2＞0 and shows gene up-regulated expression in carcinoma of the pancreas PBMC, differs from 2＜0 explanation genes and reduce expression in carcinoma of the pancreas PBMC.
Meet criterion: the median of getting genetic expression signal value in above-mentioned 10 peripheral blood mononuclear cell is as threshold value, is to raise or downward modulation is expressed with the genetic expression of the PBMC that judges tested person; The people's of tested person PBMC, the expression trend that has the expression conditions more than 7 or 7 to raise in carcinoma of the pancreas PBMC or reduce with these genes in 10 genes is consistent, and just infers the artificial carcinoma of the pancreas patient of tested person; If in the people's of tested person PBMC, in 10 genes, the expression trend that has expression conditions more than 7 or 7 and these genes to raise in carcinoma of the pancreas or reduce does not meet, and the people who just infers tested person is the normal people.
2.5 the average signal value of name carcinoma of the pancreas is higher than 5 normal peoples' gene and is considered to the up-regulated expression gene; The gene that the average signal value of 5 carcinoma of the pancreas is lower than 5 normal peoples is considered to reduce expressing gene.L48784, X83300, AI620827, AI49429, NM_020970 are the downward modulation expressing genes as can be seen according to last table; And BF433657, J02959, BC022313, NM_000904, NM_004994 are the up-regulated expression genes.
3. the median of getting gene expression amount detected result among above-mentioned 10 PBMC is as threshold value, is to raise or downward modulation is expressed with the genetic expression of the PBMC that judges tested person;
4. according to Affymetrix chip gene expression profile operational guidance, use AFFYMETRIXHUMAN GENOME U133 PLUS 2.0 ARRAY to detect this expression of group gene in the people's of tested person PBMC, screen with above-mentioned screening criteria: the people's of tested person PBMC, the expression trend that has the expression conditions more than 7 or 7 to raise in carcinoma of the pancreas PBMC or reduce with these genes in 10 genes is consistent, and just infers the artificial carcinoma of the pancreas patient of tested person; If the people's of tested person PBMC, the expression trend that has expression conditions more than 7 or 7 and these genes to raise in carcinoma of the pancreas or reduce in 10 genes does not meet, and just infers the artificial healthy population of tested person;
The present invention infers the diagnostic value (referring to embodiment 2-51) of the assortment of genes of 10 genomic constitutions of this group by k times of cross validation
K times of cross validation is that sample is divided into test group and training group, sets up model by training group sample and comes the test group sample is inferred.After repeating k time, calculate the average accuracy of inferring accuracy for k time again, promptly get the last accuracy of this model.
According to whole 25 kinds of possible permutation and combination, this experiment is divided into 25 groups in the mode of 25 groups of cross validations with sample, and every group has 8 samples (4 cancer and 4 normal) to work as learning sample, and all the other 2 is test sample book.Set up screening criteria (seeing Table 2-51) with training group sample, infer whether the test group sample is the accuracy of cancer.
The implication of various abbreviations in table 2-51:
The signal value of the tested sample-median of difference 1=,
The T mean: the mean value of tumor sample signal value,
The N mean: the mean value of normal control sample signal value,
Difference 2=T mean-N mean differs from 2＞0 and shows gene up-regulated expression in carcinoma of the pancreas PBMC, and differ from 2＜0 explanation genes and in carcinoma of the pancreas PBMC, reduce expression,
Median: the median of the signal value of gene expression amount among 8 PBMC of training group.
" meet " criterion: the median of getting gene expression amount detected result among 8 PBMC of training group is as threshold value, is to raise or downward modulation is expressed with the genetic expression of the PBMC that judges tested person; In test group, the people's of tested person PBMC, the expression trend that has the expression conditions more than 7 or 7 to raise in carcinoma of the pancreas PBMC or reduce with these genes in 10 genes is consistent, and just infers the artificial carcinoma of the pancreas patient of tested person; If the people's of tested person PBMC, the expression trend that has expression conditions more than 7 or 7 and these genes to raise in carcinoma of the pancreas or reduce in 10 genes does not meet, and just infers the artificial healthy population of tested person; (in brief, differ from 1 and differ from 2 be all negative or be all positive number, then judge to meet; Otherwise, be judged to be and do not meet.)
Embodiment 2
Operation is with reference to embodiment 1, and the result is referring to table 2.
Table 2. cross validation 1-1
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| The training group | T2 T3 | 11386.6 5944.1 | 658.7 496.2 | 730.5 1018.2 | 553.5 698.7 | 963.8 522.8 | 2495.1 3439.2 | 10854.5 6894.9 | 4182.7 3176.2 | 1516.9 5390.5 | 4475.7 7375.7 |
| The median test group differs from 1 T mean N difference in means 2 | T4 T5 N2 N3 N4 N5 T1 | 5007.4 6973.1 10817.5 13886.1 16847.6 17733.3 11102.05 6615.2 -4486.85 7327.8 14821.13 -7493.33 | 453.5 703.5 782.5 1022.6 1836.3 1396.6 743 340.3 -402.7 577.975 1259.5 -681.525 | 890.8 1478.2 1772.8 1846.8 2274.3 1949.2 1625.5 657.9 -967.6 1029.425 1960.775 -931.35 | 484.8 673.4 1117.8 1752.5 1455 1110 904.35 708.1 -196.25 602.6 1358.825 -756.225 | 745.3 642.2 1194.4 1253.1 1472.4 1367.2 1079.1 508.6 -570.5 718.525 1321.775 -603.25 | 3504.5 2453.1 2041.6 1114.9 1231.2 1311.9 2247.35 4103.5 1856.15 2972.975 1424.9 1548.075 | 10304.2 8012.7 3179.9 2481.6 3431.4 2819.9 5163.15 7571.2 2408.05 9016.575 2978.2 6038.375 | 5365.8 2728.2 1808 1132.9 1102 1757.6 2268.1 3893.3 1625.2 3863.225 1450.125 2413.1 | 4523.9 2784.2 1649.9 1678.9 1497.5 770.6 1664.4 4635.3 2970.9 3553.875 1399.225 2154.65 | 4207.6 3860.3 2940 1351.5 1300.5 2171.3 3400.15 10756.1 7355.95 4979.825 1940.825 3039 |
| Whether meet | Be | Be | Be | Be | Be | Be | Be | Be | Be | Be |
In the table 2: coincidence rate is 10/10.Infer that tested sample is a carcinoma of the pancreas.
Embodiment 3
Operation is with reference to embodiment 1, and the result is referring to table 3.
Table 3. cross validation 1-2
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T2 T3 T4 T5 N2 N3 N4 N5 N1 | 11386.6 5944.1 5007.4 6973.1 10817.5 13886.1 16847.6 17733.3 11102.05 21113.1 10011.05 7327.8 14821.13 -7493.33 | 658.7 496.2 453.5 703.5 782.5 1022.6 1836.3 1396.6 743 773 30 577.975 1259.5 -681.525 | 730.5 1018.2 890.8 1478.2 1772.8 1846.8 2274.3 1949.2 1625.5 2161.5 536 1029.425 1960.775 -931.35 | 553.5 698.7 484.8 673.4 1117.8 1752.5 1455 1110 904.35 919.2 14.85 602.6 1358.825 -756.225 | 963.8 522.8 745.3 642.2 1194.4 1253.1 1472.4 1367.2 1079.1 1460.3 381.2 718.525 1321.775 -603.25 | 2495.1 3439.2 3504.5 2453.1 2041.6 1114.9 1231.2 1311.9 2247.35 1374.7 -872.65 2972.975 1424.9 1548.075 | 10854.5 6894.9 10304.2 8012.7 3179.9 2481.6 3431.4 2819.9 5163.15 5454.1 290.95 9016.575 2978.2 6038.375 | 4182.7 3176.2 5365.8 2728.2 1808 1132.9 1102 1757.6 2268.1 1524 -744.1 3863.225 1450.125 2413.1 | 1516.9 5390.5 4523.9 2784.2 1649.9 1678.9 1497.5 770.6 1664.4 1137 -527.4 3553.875 1399.225 2154.65 | 4475.7 7375.7 4207.6 3860.3 2940 1351.5 1300.5 2171.3 3400.15 2043.6 -1356.55 4979.825 1940.825 3039 |
| Whether meet | Not | Not | Not | Not | Not | Not | Be | Not | Not | Not |
In the table 3: the rate of not meeting is 9/10.Infer that tested sample is the normal people.
Embodiment 4
Operation is with reference to embodiment 1, and the result is referring to table 4.
Table 4. cross validation 2-1
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T2 T3 T4 T5 N1 N3 N4 N5 T1 | 11386.6 5944.1 5007.4 6973.1 21113.1 13886.1 16847.6 17733.3 12636.35 6615.2 -6021.15 7327.8 17395.03 -10067.23 | 658.7 496.2 453.5 703.5 773 1022.6 1836.3 1396.6 738.25 340.3 -397.95 577.975 1257.125 -679.15 | 730.5 1018.2 890.8 1478.2 2161.5 1846.8 2274.3 1949.2 1662.5 657.9 -1004.6 1029.425 2057.95 -1028.525 | 553.5 698.7 484.8 673.4 919.2 1752.5 1455 1110 808.95 708.1 -100.85 602.6 1309.175 -706.575 | 963.8 522.8 745.3 642.2 1460.3 1253.1 1472.4 1367.2 1108.45 508.6 -599.85 718.525 1388.25 -669.725 | 2495.1 3439.2 3504.5 2453.1 1374.7 1114.9 1231.2 1311.9 1913.9 4103.5 2189.6 2972.975 1258.175 1714.8 | 10854.5 6894.9 10304.2 8012.7 5454.1 2481.6 3431.4 2819.9 6174.5 7571.2 1396.7 9016.575 3546.75 5469.825 | 4182.7 3176.2 5365.8 2728.2 1524 1132.9 1102 1757.6 2242.9 3893.3 1650.4 3863.225 1379.125 2484.1 | 1516.9 5390.5 4523.9 2784.2 1137 1678.9 1497.5 770.6 1597.9 4635.3 3037.4 3553.875 1271 2282.875 | 4475.7 7375.7 4207.6 3860.3 2043.6 1351.5 1300.5 2171.3 3015.8 10756.1 7740.3 4979.825 1716.725 3263.1 |
| Whether meet | Be | Be | Be | Be | Be | Be | Be | Be | Be | Be |
In the table 4: coincidence rate is 10/10.Infer that tested sample is a carcinoma of the pancreas.
Embodiment 5
Operation is with reference to embodiment 1, and the result is referring to table 5,
Table 5. cross validation 2-2
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T2 T3 T4 T5 N1 N3 N4 N5 N2 | 11386.6 5944.1 5007.4 6973.1 21113.1 13886.1 16847.6 17733.3 12636.35 10817.5 -1818.85 7327.8 17395.03 -10067.23 | 658.7 496.2 453.5 703.5 773 1022.6 1836.3 1396.6 738.25 782.5 44.25 577.975 1257.125 -679.15 | 730.5 1018.2 890.8 1478.2 2161.5 1846.8 2274.3 1949.2 1662.5 1772.8 110.3 1029.425 2057.95 -1028.525 | 553.5 698.7 484.8 673.4 919.2 1752.5 1455 1110 808.95 1117.8 308.85 602.6 1309.175 -706.575 | 963.8 522.8 745.3 642.2 1460.3 1253.1 1472.4 1367.2 1108.45 1194.4 85.95 718.525 1388.25 -669.725 | 2495.1 3439.2 3504.5 2453.1 1374.7 1114.9 1231.2 1311.9 1913.9 2041.6 127.7 2972.975 1258.175 1714.8 | 10854.5 6894.9 10304.2 8012.7 5454.1 2481.6 3431.4 2819.9 6174.5 3179.9 -2994.6 9016.575 3546.75 5469.825 | 4182.7 3176.2 5365.8 2728.2 1524 1132.9 1102 1757.6 2242.9 1808 -434.9 3863.225 1379.125 2484.1 | 1516.9 5390.5 4523.9 2784.2 1137 1678.9 1497.5 770.6 1597.9 1649.9 52 3553.875 1271 2282.875 | 4475.7 7375.7 4207.6 3860.3 2043.6 1351.5 1300.5 2171.3 3015.8 2940 -75.8 4979.825 1716.725 3263.1 |
| Whether meet | Be | Not | Not | Not | Not | Be | Not | Not | Be | Not |
In the table 5: the rate of not meeting is 7/10.Infer the PBMC of tested sample for the normal people.
Embodiment 6
Operation is with reference to embodiment 1, and the result is referring to table 6.
Table 6. cross validation 3-1
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| The training group | T2 T3 T4 T5 | 11386.6 5944.1 5007.4 6973.1 | 658.7 496.2 453.5 703.5 | 730.5 1018.2 890.8 1478.2 | 553.5 698.7 484.8 673.4 | 963.8 522.8 745.3 642.2 | 2495.1 3439.2 3504.5 2453.1 | 10854.5 6894.9 10304.2 8012.7 | 4182.7 3176.2 5365.8 2728.2 | 1516.9 5390.5 4523.9 2784.2 | 4475.7 7375.7 4207.6 3860.3 |
| The median test group differs from 1 T mean N difference in means 2 | N1 N2 N4 N5 T1 | 21113.1 10817.5 16847.6 17733.3 11102.05 6615.2 -4486.85 7327.8 16627.88 -9300.075 | 773 782.5 1836.3 1396.6 738.25 340.3 -397.95 577.975 1197.1 -619.125 | 2161.5 1772.8 2274.3 1949.2 1625.5 657.9 -967.6 1029.425 2039.45 -1010.025 | 919.2 1117.8 1455 1110 808.95 708.1 -100.85 602.6 1150.5 -547.9 | 1460.3 1194.4 1472.4 1367.2 1079.1 508.6 -570.5 718.525 1373.575 -655.05 | 1374.7 2041.6 1231.2 1311.9 2247.35 4103.5 1856.15 2972.975 1489.85 1483.125 | 5454.1 3179.9 3431.4 2819.9 6174.5 7571.2 1396.7 9016.575 3721.325 5295.25 | 1524 1808 1102 1757.6 2268.1 3893.3 1625.2 3863.225 1547.9 2315.325 | 1137 1649.9 1497.5 770.6 1583.4 4635.3 3051.9 3553.875 1263.75 2290.125 | 2043.6 2940 1300.5 2171.3 3400.15 10756.1 7355.95 4979.825 2113.85 2865.975 |
| Whether meet | Be | Be | Be | Be | Be | Be | Be | Be | Be | Be |
In the table 6: coincidence rate is 10/10.Infer that tested sample is carcinoma of the pancreas patient's PBMC.
Embodiment 7
Operation is with reference to embodiment 1, and the result is referring to table 7.
Table 7. cross validation 3-2
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T2 T3 T4 T5 N1 N2 N4 N5 N3 | 11386.6 5944.1 5007.4 6973.1 21113.1 10817.5 16847.6 17733.3 11102.05 13886.1 2784.05 7327.8 16627.88 -9300.075 | 658.7 496.2 453.5 703.5 773 782.5 1836.3 1396.6 738.25 1022.6 284.35 577.975 1197.1 -619.125 | 730.5 1018.2 890.8 1478.2 2161.5 1772.8 2274.3 1949.2 1625.5 1846.8 221.3 1029.425 2039.45 -1010.025 | 553.5 698.7 484.8 673.4 919.2 1117.8 1455 1110 808.95 1752.5 943.55 602.6 1150.5 -547.9 | 963.8 522.8 745.3 642.2 1460.3 1194.4 1472.4 1367.2 1079.1 1253.1 174 718.525 1373.575 -655.05 | 2495.1 3439.2 3504.5 2453.1 1374.7 2041.6 1231.2 1311.9 2247.35 1114.9 -1132.45 2972.975 1489.85 1483.125 | 10854.5 6894.9 10304.2 8012.7 5454.1 3179.9 3431.4 2819.9 6174.5 2481.6 -3692.9 9016.575 3721.325 5295.25 | 4182.7 3176.2 5365.8 2728.2 1524 1808 1102 1757.6 2268.1 1132.9 -1135.2 3863.225 1547.9 2315.325 | 1516.9 5390.5 4523.9 2784.2 1137 1649.9 1497.5 770.6 1583.4 1678.9 95.5 3553.875 1263.75 2290.125 | 4475.7 7375.7 4207.6 3860.3 2043.6 2940 1300.5 2171.3 3400.15 1351.5 -2048.65 4979.825 2113.85 2865.975 |
| Whether meet | Not | Not | Not | Not | Not | Not | Not | Not | Be | Not |
In the table 7: coincidence rate is 9/10.Infer the PBMC of tested sample for the normal people.
Embodiment 8
Operation is with reference to embodiment 1, and the result is referring to table 8,
Table 8. cross validation 4-1
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| The training group | T2 | 11386.6 | 658.7 | 730.5 | 553.5 | 963.8 | 2495.1 | 10854.5 | 4182.7 | 1516.9 | 4475.7 |
| The median test group differs from 1 T mean N difference in means 2 | T3 T4 T5 N1 N2 N3 N5 T1 | 5944.1 5007.4 6973.1 21113.1 10817.5 13886.1 17733.3 11102.05 6615.2 -4486.85 7327.8 15887.5 -8559.7 | 496.2 453.5 703.5 773 782.5 1022.6 1396.6 738.25 340.3 -397.95 577.975 993.675 -415.7 | 1018.2 890.8 1478.2 2161.5 1772.8 1846.8 1949.2 1625.5 657.9 -967.6 1029.425 1932.575 -903.15 | 698.7 484.8 673.4 919.2 1117.8 1752.5 1110 808.95 708.1 -100.85 602.6 1224.875 -622.275 | 522.8 745.3 642.2 1460.3 1194.4 1253.1 1367.2 1079.1 508.6 -570.5 718.525 1318.75 -600.225 | 3439.2 3504.5 2453.1 1374.7 2041.6 1114.9 1311.9 2247.35 4103.5 1856.15 2972.975 1460.775 1512.2 | 6894.9 10304.2 8012.7 5454.1 3179.9 2481.6 2819.9 6174.5 7571.2 1396.7 9016.575 3483.875 5532.7 | 3176.2 5365.8 2728.2 1524 1808 1132.9 1757.6 2268.1 3893.3 1625.2 3863.225 1555.625 2307.6 | 5390.5 4523.9 2784.2 1137 1649.9 1678.9 770.6 1664.4 4635.3 2970.9 3553.875 1309.1 2244.775 | 7375.7 4207.6 3860.3 2043.6 2940 1351.5 2171.3 3400.15 10756.1 7355.95 4979.825 2126.6 2853.225 |
| Whether meet | Be | Be | Be | Be | Be | Be | Be | Be | Be | Be |
In the table 8: coincidence rate is 10/10.Infer that tested sample is a carcinoma of the pancreas.
Embodiment 9
Operation is with reference to embodiment 1, and the result is referring to table 9,
Table 9. cross validation 4-2
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T2 T3 T4 T5 N1 N2 N3 N5 N4 | 11386.6 5944.1 5007.4 6973.1 21113.1 10817.5 13886.1 17733.3 11102.05 16847.6 5745.55 7327.8 15887.5 -8559.7 | 658.7 496.2 453.5 703.5 773 782.5 1022.6 1396.6 738.25 1836.3 1098.05 577.975 993.675 -415.7 | 730.5 1018.2 890.8 1478.2 2161.5 1772.8 1846.8 1949.2 1625.5 2274.3 648.8 1029.425 1932.575 -903.15 | 553.5 698.7 484.8 673.4 919.2 1117.8 1752.5 1110 808.95 1455 646.05 602.6 1224.875 -622.275 | 963.8 522.8 745.3 642.2 1460.3 1194.4 1253.1 1367.2 1079.1 1472.4 393.3 718.525 1318.75 -600.225 | 2495.1 3439.2 3504.5 2453.1 1374.7 2041.6 1114.9 1311.9 2247.35 1231.2 -1016.15 2972.975 1460.775 1512.2 | 10854.5 6894.9 10304.2 8012.7 5454.1 3179.9 2481.6 2819.9 6174.5 3431.4 -2743.1 9016.575 3483.875 5532.7 | 4182.7 3176.2 5365.8 2728.2 1524 1808 1132.9 1757.6 2268.1 1102 -1166.1 3863.225 1555.625 2307.6 | 1516.9 5390.5 4523.9 2784.2 1137 1649.9 1678.9 770.6 1664.4 1497.5 -166.9 3553.875 1309.1 2244.775 | 4475.7 7375.7 4207.6 3860.3 2043.6 2940 1351.5 2171.3 3400.15 1300.5 -2099.65 4979.825 2126.6 2853.225 |
| Whether meet | Not | Not | Not | Not | Not | Not | Not | Not | Not | Not |
In the table 9: the rate of not meeting is 10/10.Infer the PBMC of tested sample for the normal people.
Embodiment 10
Operation is with reference to embodiment 1, and the result is referring to table 10,
Table 10. cross validation 5-1
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T2 T3 T4 T5 N1 N2 N3 N4 T1 | 11386.6 5944.1 5007.4 6973.1 21113.1 10817.5 13886.1 16847.6 11102.05 6615.2 -4486.85 7327.8 15666.075 -8338.275 | 658.7 496.2 453.5 703.5 773 782.5 1022.6 1836.3 738.25 340.3 -397.95 577.975 1103.6 -525.625 | 730.5 1018.2 890.8 1478.2 2161.5 1772.8 1846.8 2274.3 1625.5 657.9 -967.6 1029.425 2013.85 -984.425 | 553.5 698.7 484.8 673.4 919.2 1117.8 1752.5 1455 808.95 708.1 -100.85 602.6 1311.125 -708.525 | 963.8 522.8 745.3 642.2 1460.3 1194.4 1253.1 1472.4 1079.1 508.6 -570.5 718.525 1345.05 -626.525 | 2495.1 3439.2 3504.5 2453.1 1374.7 2041.6 1114.9 1231.2 2247.35 4103.5 1856.15 2972.975 1440.6 1532.375 | 10854.5 6894.9 10304.2 8012.7 5454.1 3179.9 2481.6 3431.4 6174.5 7571.2 1396.7 9016.575 3636.75 5379.825 | 4182.7 3176.2 5365.8 2728.2 1524 1808 1132.9 1102 2268.1 3893.3 1625.2 3863.225 1391.725 2471.5 | 1516.9 5390.5 4523.9 2784.2 1137 1649.9 1678.9 1497.5 1664.4 4635.3 2970.9 3553.875 1490.825 2063.05 | 4475.7 7375.7 4207.6 3860.3 2043.6 2940 1351.5 1300.5 3400.15 10756.1 7355.95 4979.825 1908.9 3070.925 |
| Whether meet | Be | Be | Be | Be | Be | Be | Be | Be | Be | Be |
In the table 10: coincidence rate is 10/10.Infer that tested sample is carcinoma of the pancreas patient's PBMC.
Embodiment 11
Operation is with reference to embodiment 1, and the result is referring to table 11,
Table 11. cross validation 5-2
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N mean | T2 T3 T4 T5 N1 N2 N3 N4 N5 | 11386.6 5944.1 5007.4 6973.1 21113.1 10817.5 13886.1 16847.6 11102.05 17733.3 6631.25 7327.8 15666.075 | 658.7 496.2 453.5 703.5 773 782.5 1022.6 1836.3 738.25 1396.6 658.35 577.975 1103.6 | 730.5 1018.2 890.8 1478.2 2161.5 1772.8 1846.8 2274.3 1625.5 1949.2 323.7 1029.425 2013.85 | 553.5 698.7 484.8 673.4 919.2 1117.8 1752.5 1455 808.95 1110 301.05 602.6 1311.125 | 963.8 522.8 745.3 642.2 1460.3 1194.4 1253.1 1472.4 1079.1 1367.2 288.1 718.525 1345.05 | 2495.1 3439.2 3504.5 2453.1 1374.7 2041.6 1114.9 1231.2 2247.35 1311.9 -935.45 2972.975 1440.6 | 10854.5 6894.9 10304.2 8012.7 5454.1 3179.9 2481.6 3431.4 6174.5 2819.9 -3354.6 9016.575 3636.75 | 4182.7 3176.2 5365.8 2728.2 1524 1808 1132.9 1102 2268.1 1757.6 -510.5 3863.225 1391.725 | 1516.9 5390.5 4523.9 2784.2 1137 1649.9 1678.9 1497.5 1664.4 770.6 -893.8 3553.875 1490.825 | 4475.7 7375.7 4207.6 3860.3 2043.6 2940 1351.5 1300.5 3400.15 2171.3 -1228.85 4979.825 1908.9 |
| Differ from 2 | -8338.275 | -525.625 | -984.425 | -708.525 | -626.525 | 1532.375 | 5379.825 | 2471.5 | 2063.05 | 3070.925 | |
| Whether meet | Not | Not | Not | Not | Not | Not | Not | Not | Not | Not |
In the table 11: the rate of not meeting is 10/10.Infer the PBMC of tested sample for the normal people.
Embodiment 12
Operation is with reference to embodiment 1, and the result is referring to table 12,
Table 12. cross validation 6-1
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T1 T3 T4 T5 N2 N3 N4 N5 | 6615.2 5944.1 5007.4 6973.1 10817.5 13886.1 16847.6 17733.3 8895.3 11386.6 2491.3 6134.95 14821.125 -8686.175 | 340.3 496.2 453.5 703.5 782.5 1022.6 1836.3 1396.6 743 658.7 -84.3 498.375 1259.5 -761.125 | 657.9 1018.2 890.8 1478.2 1772.8 1846.8 2274.3 1949.2 1625.5 730.5 -895 1011.275 1960.775 -949.5 | 708.1 698.7 484.8 673.4 1117.8 1752.5 1455 1110 909.05 553.5 -355.55 641.25 1358.825 -717.575 | 508.6 522.8 745.3 642.2 1194.4 1253.1 1472.4 1367.2 969.85 963.8 -6.05 604.725 1321.775 -717.05 | 4103.5 3439.2 3504.5 2453.1 2041.6 1114.9 1231.2 1311.9 2247.35 2495.1 247.75 3375.075 1424.9 1950.175 | 7571.2 6894.9 10304.2 8012.7 3179.9 2481.6 3431.4 2819.9 5163.15 10854.5 5691.35 8195.75 2978.2 5217.55 | 3893.3 3176.2 5365.8 2728.2 1808 1132.9 1102 1757.6 2268.1 4182.7 1914.6 3790.875 1450.125 2340.75 | 4635.3 5390.5 4523.9 2784.2 1649.9 1678.9 1497.5 770.6 2231.55 1516.9 -714.65 4333.475 1399.225 2934.25 | 10756.1 7375.7 4207.6 3860.3 2940 1351.5 1300.5 2171.3 3400.15 4475.7 1075.55 6549.925 1940.825 4609.1 |
| Whether meet | Whether meet | Not | Be | Be | Be | Be | Be | Be | Be | Not | Be |
In the table 12: coincidence rate is 8/10.Infer that tested sample is a carcinoma of the pancreas.
Embodiment 13
Operation is with reference to embodiment 1, and the result is referring to table 13,
Table 13 cross validation 6-2
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| The training group | T1 T3 T4 T5 N2 N3 N4 N5 | 6615.2 5944.1 5007.4 6973.1 10817.5 13886.1 16847.6 17733.3 | 340.3 496.2 453.5 703.5 782.5 1022.6 1836.3 1396.6 | 657.9 1018.2 890.8 1478.2 1772.8 1846.8 2274.3 1949.2 | 708.1 698.7 484.8 673.4 1117.8 1752.5 1455 1110 | 508.6 522.8 745.3 642.2 1194.4 1253.1 1472.4 1367.2 | 4103.5 3439.2 3504.5 2453.1 2041.6 1114.9 1231.2 1311.9 | 7571.2 6894.9 10304.2 8012.7 3179.9 2481.6 3431.4 2819.9 | 3893.3 3176.2 5365.8 2728.2 1808 1132.9 1102 1757.6 | 4635.3 5390.5 4523.9 2784.2 1649.9 1678.9 1497.5 770.6 | 10756.1 7375.7 4207.6 3860.3 2940 1351.5 1300.5 2171.3 |
| The median test group differs from 1 T mean N difference in means 2 | N1 | 8895.3 21113.1 12217.8 6134.95 14821.125 -8686.175 | 743 773 30 498.375 1259.5 -761.125 | 1625.5 2161.5 536 1011.275 1960.775 -949.5 | 909.05 919.2 10.15 641.25 1358.825 -717.575 | 969.85 1460.3 490.45 604.725 1321.775 -717.05 | 2247.35 1374.7 -872.65 3375.075 1424.9 1950.175 | 5163.15 5454.1 290.95 8195.75 2978.2 5217.55 | 2268.1 1524 -744.1 3790.875 1450.125 2340.75 | 2231.55 1137 -1094.55 4333.475 1399.225 2934.25 | 3400.15 2043.6 -1356.55 6549.925 1940.825 4609.1 |
| Whether meet | Not | Not | Not | Not | Not | Not | Be | Not | Not | Not |
In the table 13: the rate of not meeting is 9/10.Infer the PBMC of tested sample for the normal people.
Embodiment 14
Operation is with reference to embodiment 1, and the result is referring to table 14,
Table 14. cross validation 7-1
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T1 T3 T4 T5 N1 N3 N4 N5 T2 | 6615.2 5944.1 5007.4 6973.1 21113.1 13886.1 16847.6 17733.3 10429.6 11386.6 957 6134.95 17395.025 -11260.075 | 340.3 496.2 453.5 703.5 773 1022.6 1836.3 1396.6 738.25 658.7 -79.55 498.375 1257.125 -758.75 | 657.9 1018.2 890.8 1478.2 2161.5 1846.8 2274.3 1949.2 1662.5 730.5 -932 1011.275 2057.95 -1046.675 | 708.1 698.7 484.8 673.4 919.2 1752.5 1455 1110 813.65 553.5 -260.15 641.25 1309.175 -667.925 | 508.6 522.8 745.3 642.2 1460.3 1253.1 1472.4 1367.2 999.2 963.8 -35.4 604.725 1388.25 -783.525 | 4103.5 3439.2 3504.5 2453.1 1374.7 1114.9 1231.2 1311.9 1913.9 2495.1 581.2 3375.075 1258.175 2116.9 | 7571.2 6894.9 10304.2 8012.7 5454.1 2481.6 3431.4 2819.9 6174.5 10854.5 4680 8195.75 3546.75 4649 | 3893.3 3176.2 5365.8 2728.2 1524 1132.9 1102 1757.6 2242.9 4182.7 1939.8 3790.875 1379.125 2411.75 | 4635.3 5390.5 4523.9 2784.2 1137 1678.9 1497.5 770.6 2231.55 1516.9 -714.65 4333.475 1271 3062.475 | 10756.1 7375.7 4207.6 3860.3 2043.6 1351.5 1300.5 2171.3 3015.8 4475.7 1459.9 6549.925 1716.725 4833.2 |
| Whether meet | Not | Be | Be | Be | Be | Be | Be | Be | Not | Be |
In the table 14: coincidence rate is 8/10.Infer that tested sample is carcinoma of the pancreas patient's PBMC.
Embodiment 15
Operation is with reference to embodiment 1, and the result is referring to table 15,
Table 15. cross validation 7-2
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| The training group | T1 T3 T4 | 6615.2 5944.1 5007.4 | 340.3 496.2 453.5 | 657.9 1018.2 890.8 | 708.1 698.7 484.8 | 508.6 522.8 745.3 | 4103.5 3439.2 3504.5 | 7571.2 6894.9 10304.2 | 3893.3 3176.2 5365.8 | 4635.3 5390.5 4523.9 | 10756.1 7375.7 4207.6 |
| The median test group differs from 1 T mean N difference in means 2 | T5 N1 N3 N4 N5 N2 | 6973.1 21113.1 13886.1 16847.6 17733.3 10429.6 10817.5 387.9 6134.95 17395.025 -11260.075 | 703.5 773 1022.6 1836.3 1396.6 738.25 782.5 44.25 498.375 1257.125 -758.75 | 1478.2 2161.5 1846.8 2274.3 1949.2 1662.5 1772.8 110.3 1011.275 2057.95 -1046.675 | 673.4 919.2 1752.5 1455 1110 813.65 1117.8 304.15 641.25 1309.175 -667.925 | 642.2 1460.3 1253.1 1472.4 1367.2 999.2 1194.4 195.2 604.725 1388.25 -783.525 | 2453.1 1374.7 1114.9 1231.2 1311.9 1913.9 2041.6 127.7 3375.075 1258.175 2116.9 | 8012.7 5454.1 2481.6 3431.4 2819.9 6174.5 3179.9 -2994.6 8195.75 3546.75 4649 | 2728.2 1524 1132.9 1102 1757.6 2242.9 1808 -434.9 3790.875 1379.125 2411.75 | 2784.2 1137 1678.9 1497.5 770.6 2231.55 1649.9 -581.65 4333.475 1271 3062.475 | 3860.3 2043.6 1351.5 1300.5 2171.3 3015.8 2940 -75.8 6549.925 1716.725 4833.2 |
| Whether meet | Not | Not | Not | Not | Not | Be | Not | Not | Not | Not |
In the table 15: the rate of not meeting is 9/10.Infer the PBMC of tested sample for the normal people.
Embodiment 16
Operation is with reference to embodiment 1, and the result is referring to table 16,
Table 16 cross validation 8-1
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T1 T3 T4 T5 N1 N2 N4 N5 T2 | 6615.2 5944.1 5007.4 6973.1 21113.1 10817.5 16847.6 17733.3 8895.3 11386.6 2491.3 6134.95 16627.875 -10492.925 | 340.3 496.2 453.5 703.5 773 782.5 1836.3 1396.6 738.25 658.7 -79.55 498.375 1197.1 -698.725 | 657.9 1018.2 890.8 1478.2 2161.5 1772.8 2274.3 1949.2 1625.5 730.5 -895 1011.275 2039.45 -1028.175 | 708.1 698.7 484.8 673.4 919.2 1117.8 1455 1110 813.65 553.5 -260.15 641.25 1150.5 -509.25 | 508.6 522.8 745.3 642.2 1460.3 1194.4 1472.4 1367.2 969.85 963.8 -6.05 604.725 1373.575 -768.85 | 4103.5 3439.2 3504.5 2453.1 1374.7 2041.6 1231.2 1311.9 2247.35 2495.1 247.75 3375.075 1489.85 1885.225 | 7571.2 6894.9 10304.2 8012.7 5454.1 3179.9 3431.4 2819.9 6174.5 10854.5 4680 8195.75 3721.325 4474.425 | 3893.3 3176.2 5365.8 2728.2 1524 1808 1102 1757.6 2268.1 4182.7 1914.6 3790.875 1547.9 2242.975 | 4635.3 5390.5 4523.9 2784.2 1137 1649.9 1497.5 770.6 2217.05 1516.9 -700.15 4333.475 1263.75 3069.725 | 10756.1 7375.7 4207.6 3860.3 2043.6 2940 1300.5 2171.3 3400.15 4475.7 1075.55 6549.925 2113.85 4436.075 |
| Whether meet | Not | Be | Be | Be | Be | Be | Be | Be | Not | Be |
In the table 16: coincidence rate is 8/10.Infer that tested sample is carcinoma of the pancreas patient's PBMC.
Embodiment 17
Operation is with reference to embodiment 1, and the result is referring to table 17,
Table 17. cross validation 8-2
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T1 T3 T4 T5 N1 N2 N4 N5 N3 | 6615.2 5944.1 5007.4 6973.1 21113.1 10817.5 16847.6 17733.3 8895.3 13886.1 49908 6134.95 16627.875 -10492.925 | 340.3 496.2 453.5 703.5 773 782.5 1836.3 1396.6 738.25 1022.6 284.35 498.375 1197.1 -698.725 | 657.9 1018.2 890.8 1478.2 2161.5 1772.8 2274.3 1949.2 1625.5 1846.8 221.3 1011.275 2039.45 -1028.175 | 708.1 698.7 484.8 673.4 919.2 1117.8 1455 1110 813.65 1752.5 938.85 641.25 1150.5 -509.25 | 508.6 522.8 745.3 642.2 1460.3 1194.4 1472.4 1367.2 969.85 1253.1 283.25 604.725 1373.575 -768.85 | 4103.5 3439.2 3504.5 2453.1 1374.7 2041.6 1231.2 1311.9 2247.35 1114.9 -1132.45 3375.075 1489.85 1885.225 | 7571.2 6894.9 10304.2 8012.7 5454.1 3179.9 3431.4 2819.9 6174.5 2481.6 -3692.9 8195.75 3721.325 4474.425 | 3893.3 3176.2 5365.8 2728.2 1524 1808 1102 1757.6 2268.1 1132.9 -1135.2 3790.875 1547.9 2242.975 | 4635.3 5390.5 4523.9 2784.2 1137 1649.9 1497.5 770.6 2217.05 1678.9 -538.15 4333.475 1263.75 3069.725 | 10756.1 7375.7 4207.6 3860.3 2043.6 2940 1300.5 2171.3 3400.15 1351.5 -2048.65 6549.925 2113.85 4436.075 |
| Whether meet | Not | Not | Not | Not | Not | Not | Not | Not | Not | Not |
In the table 17: the rate of not meeting is 10/10.Infer the PBMC of tested sample for the normal people.
Embodiment 18
Operation is with reference to embodiment 1, and the result is referring to table 18,
Table 18. cross validation 9-1
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T1 T3 T4 T5 N1 N2 N3 N5 T2 | 6615.2 5944.1 5007.4 6973.1 21113.1 10817.5 13886.1 17733.3 8895.3 11386.6 2491.3 6134.95 15887.5 -9752.55 | 340.3 496.2 453.5 703.5 773 782.5 1022.6 1396.6 738.25 658.7 -79.55 498.375 993.675 -495.3 | 657.9 1018.2 890.8 1478.2 2161.5 1772.8 1846.8 1949.2 1625.5 730.5 -895 1011.275 1932.575 -921.3 | 708.1 698.7 484.8 673.4 919.2 1117.8 1752.5 1110 813.65 553.5 -260.15 641.25 1224.875 -583.625 | 508.6 522.8 745.3 642.2 1460.3 1194.4 1253.1 1367.2 969.85 963.8 -6.05 604.725 1318.75 -714.025 | 4103.5 3439.2 3504.5 2453.1 1374.7 2041.6 1114.9 1311.9 2247.35 2495.1 247.75 3375.075 1460.775 1914.3 | 7571.2 6894.9 10304.2 8012.7 5454.1 3179.9 2481.6 2819.9 6174.5 10854.5 4680 8195.75 3483.875 4711.875 | 3893.3 3176.2 5365.8 2728.2 1524 1808 1132.9 1757.6 2268.1 4182.7 1914.6 3790.875 1555.625 2235.25 | 4635.3 5390.5 4523.9 2784.2 1137 1649.9 1678.9 770.6 2231.55 1516.9 -714.65 4333.475 1309.1 3024.375 | 10756.1 7375.7 4207.6 3860.3 2043.6 2940 1351.5 2171.3 3400.15 4475.7 1075.55 6549.925 2126.6 4423.325 |
| Whether meet | Not | Be | Be | Be | Be | Be | Be | Be | Not | Be |
In the table 18: coincidence rate is 8/10.Infer that tested sample is carcinoma of the pancreas patient's PBMC.
Embodiment 19
Operation is with reference to embodiment 1, and the result is referring to table 19,
Table 19 cross validation 9-2
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T1 T3 T4 T5 N1 N2 N3 N5 N4 | 6615.2 5944.1 5007.4 6973.1 21113.1 10817.5 13886.1 17733.3 8895.3 16847.6 7952.3 6134.95 15887.5 -9752.55 | 340.3 496.2 453.5 703.5 773 782.5 1022.6 1396.6 738.25 1836.3 1098.05 498.375 993.675 -495.3 | 657.9 1018.2 890.8 1478.2 2161.5 1772.8 1846.8 1949.2 1625.5 2274.3 648.8 1011.275 1932.575 -921.3 | 708.1 698.7 484.8 673.4 919.2 1117.8 1752.5 1110 813.65 1455 641.35 641.25 1224.875 -583.625 | 508.6 522.8 745.3 642.2 1460.3 1194.4 1253.1 1367.2 969.85 1472.4 502.55 604.725 1318.75 -714.025 | 4103.5 3439.2 3504.5 2453.1 1374.7 2041.6 1114.9 1311.9 2247.35 1231.2 -1016.15 3375.075 1460.775 1914.3 | 7571.2 6894.9 10304.2 8012.7 5454.1 3179.9 2481.6 2819.9 6174.5 3431.4 -2743.1 8195.75 3483.875 4711.875 | 3893.3 3176.2 5365.8 2728.2 1524 1808 1132.9 1757.6 2268.1 1102 -1166.1 3790.875 1555.625 2235.25 | 4635.3 5390.5 4523.9 2784.2 1137 1649.9 1678.9 770.6 2231.55 1497.5 -734.05 4333.475 1309.1 3024.375 | 10756.1 7375.7 4207.6 3860.3 2043.6 2940 1351.5 2171.3 3400.15 1300.5 -2099.65 6549.925 2126.6 4423.325 |
| Whether meet | Not | Not | Not | Not | Not | Not | Not | Not | Not | Not |
In the table 19: the rate of not meeting is 10/10.Infer the PBMC of tested sample for the normal people.
Embodiment 20
Operation is with reference to embodiment 1, and the result is referring to table 20,
Table 20. cross validation 10-1
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 | T1 T3 T4 T5 N1 N2 N3 N4 T2 | 6615.2 5944.1 5007.4 6973.1 21113.1 10817.5 13886.1 16847.6 8895.3 11386.6 2491.3 | 340.3 496.2 453.5 703.5 773 782.5 1022.6 1836.3 738.25 658.7 -79.55 | 657.9 1018.2 890.8 1478.2 2161.5 1772.8 1846.8 2274.3 1625.5 730.5 -895 | 708.1 698.7 484.8 673.4 919.2 1117.8 1752.5 1455 813.65 553.5 -260.15 | 508.6 522.8 745.3 642.2 1460.3 1194.4 1253.1 1472.4 969.85 963.8 -6.05 | 4103.5 3439.2 3504.5 2453.1 1374.7 2041.6 1114.9 1231.2 2247.35 2495.1 247.75 | 7571.2 6894.9 10304.2 8012.7 5454.1 3179.9 2481.6 3431.4 6174.5 10854.5 4680 | 3893.3 3176.2 5365.8 2728.2 1524 1808 1132.9 1102 2268.1 4182.7 1914.6 | 4635.3 5390.5 4523.9 2784.2 1137 1649.9 1678.9 1497.5 2231.55 1516.9 -714.65 | 10756.1 7375.7 4207.6 3860.3 2043.6 2940 1351.5 1300.5 3400.15 4475.7 1075.55 |
| T mean N difference in means 2 | 6134.95 15666.075 9531.125 | 498.375 1103.6 -605.225 | 1011.275 2013.85 -1002.575 | 641.25 1311.125 -669.875 | 604.725 1345.05 -740.325 | 3375.075 1440.6 1934.475 | 8195.75 3636.75 4559 | 3790.875 1391.725 2399.15 | 4333.475 1490.825 2842.65 | 6549.925 1908.9 4641.025 | |
| Whether meet | Not | Be | Be | Be | Be | Be | Be | Be | Not | Be |
In the table 20: coincidence rate is 8/10.Infer that tested sample is carcinoma of the pancreas patient's PBMC.
Embodiment 21
Operation is with reference to embodiment 1, and the result is referring to table 21,
Table 21. cross validation 10-2
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T1 T3 T4 T5 N1 N2 N3 N4 N5 | 6615.2 5944.1 5007.4 6973.1 21113.1 10817.5 13886.1 16847.6 8895.3 17733.3 8838 6134.95 15666.075 -9531.125 | 340.3 496.2 453.5 703.5 773 782.5 1022.6 1836.3 738.25 1396.6 658.35 498.375 1103.6 -605.225 | 657.9 1018.2 890.8 1478.2 2161.5 1772.8 1846.8 2274.3 1625.5 1949.2 323.7 1011.275 2013.85 -1002.575 | 708.1 698.7 484.8 673.4 919.2 1117.8 1752.5 1455 813.65 1110 296.35 641.25 1311.125 -669.875 | 508.6 522.8 745.3 642.2 1460.3 1194.4 1253.1 1472.4 969.85 1367.2 397.35 604.725 1345.05 -740.325 | 4103.5 3439.2 3504.5 2453.1 1374.7 2041.6 1114.9 1231.2 2247.35 1311.9 -935.45 3375.075 1440.6 1934.475 | 7571.2 6894.9 10304.2 8012.7 5454.1 3179.9 2481.6 3431.4 6174.5 2819.9 -3354.6 8195.75 3636.75 4559 | 3893.3 3176.2 5365.8 2728.2 1524 1808 1132.9 1102 2268.1 1757.6 -510.5 3790.875 1391.725 2399.15 | 4635.3 5390.5 4523.9 2784.2 1137 1649.9 1678.9 1497.5 2231.55 770.6 -1460.95 4333.475 1490.825 2842.65 | 10756.1 7375.7 4207.6 3860.3 2043.6 2940 1351.5 1300.5 3400.15 2171.3 -1228.85 6549.925 1908.9 4641.025 |
| Whether meet | Not | Not | Not | Not | Not | Not | Not | Not | Not | Not |
In the table 21: the rate of not meeting is 10/10.Infer the PBMC of tested sample for the normal people.
Embodiment 22
Operation is with reference to embodiment 1, and the result is referring to table 22.
Table 22. cross validation 11-1
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| The training group | T1 T2 | 6615.2 11386.6 | 340.3 658.7 | 657.9 730.5 | 708.1 553.5 | 508.6 963.8 | 4103.5 2495.1 | 7571.2 10854.5 | 3893.3 4182.7 | 4635.3 1516.9 | 10756.1 4475.7 |
| The median test group differs from 1 T mean N difference in means 2 | T4 T5 N2 N3 N4 N5 T3 | 5007.4 6973.1 10817.5 13886.1 16847.6 17733.3 11102.05 5944.1 -5157.95 7495.575 14821.125 -7325.55 | 453.5 703.5 782.5 1022.6 1836.3 1396.6 743 496.2 -246.8 539 1259.5 -720.5 | 890.8 1478.2 1772.8 1846.8 2274.3 1949.2 1625.5 1018.2 -607.3 939.35 1960.775 -1021.425 | 484.8 673.4 1117.8 1752.5 1455 1110 909.05 698.7 -210.35 604.95 1358.825 -753.875 | 745.3 642.2 1194.4 1253.1 1472.4 1367.2 1079.1 522.8 -556.3 714.975 1321.775 -606.8 | 3504.5 2453.1 2041.6 1114.9 1231.2 1311.9 2247.35 3439.2 1191.85 3139.05 1424.9 1714.15 | 10304.2 8012.7 3179.9 2481.6 3431.4 2819.9 5501.3 6894.9 1393.6 9185.65 2978.2 6207.45 | 5365.8 2728.2 1808 1132.9 1102 1757.6 2268.1 3176.2 908.1 4042.5 1450.125 2592.375 | 4523.9 2784.2 1649.9 1678.9 1497.5 770.6 1664.4 5390.5 3726.1 3365.075 1399.225 1965.85 | 4207.6 3860.3 2940 1351.5 1300.5 2171.3 3400.15 7375.7 3975.55 5824.925 1940.825 3884.1 |
| Whether meet | Be | Be | Be | Be | Be | Be | Be | Be | Be | Be |
In the table 22: coincidence rate is 10/10.Infer that tested sample is carcinoma of the pancreas patient's PBMC.
Embodiment 23
Operation is with reference to embodiment 1, and the result is referring to table 23.
Table 23. cross validation 11-2
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T1 T2 T4 T5 N2 N3 N4 N5 N1 | 6615.2 11386.6 5007.4 6973.1 10817.5 13886.1 16847.6 17733.3 11102.05 21113.1 10011.05 7495.575 14821.125 -7325.55 | 340.3 658.7 453.5 703.5 782.5 1022.6 1836.3 1396.6 743 773 30 539 1259.5 -720.5 | 657.9 730.5 890.8 1478.2 1772.8 1846.8 2274.3 1949.2 1625.5 2161.5 536 939.35 1960.775 -1021.425 | 708.1 553.5 484.8 673.4 1117.8 1752.5 1455 1110 909.05 919.2 10.15 604.95 1358.825 -753.875 | 508.6 963.8 745.3 642.2 1194.4 1253.1 1472.4 1367.2 1079.1 1460.3 381.2 714.975 1321.775 -606.8 | 4103.5 2495.1 3504.5 2453.1 2041.6 1114.9 1231.2 1311.9 2247.35 1374.7 872.65 3139.05 1424.9 1714.15 | 7571.2 10854.5 10304.2 8012.7 3179.9 2481.6 3431.4 2819.9 5501.3 5454.1 47.2 9185.65 2978.2 6207.45 | 3893.3 4182.7 5365.8 2728.2 1808 1132.9 1102 1757.6 2268.1 1524 -744.1 4042.5 1450.125 2592.375 | 4635.3 1516.9 4523.9 2784.2 1649.9 1678.9 1497.5 770.6 1664.4 1137 -527.4 3365.075 1399.225 1965.85 | 10756.1 4475.7 4207.6 3860.3 2940 1351.5 1300.5 2171.3 3400.15 2043.6 -1356.55 5824.925 1940.825 3884.1 |
| Whether meet | Not | Not | Not | Not | Not | Not | Not | Not | Not | Not |
In the table 23: the rate of not meeting is 10/10.Infer the PBMC of tested sample for the normal people.
Embodiment 24
Operation is with reference to embodiment 1, and the result is referring to table 24.
Table 24 cross validation 12-1
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T1 T2 T4 T5 N1 N3 N4 N5 T3 | 6615.2 11386.6 5007.4 6973.1 21113.1 13886.1 16847.6 17733.3 12636.35 5944.1 -6692.25 7495.575 17395.025 -9899.45 | 340.3 658.7 453.5 703.5 773 1022.6 1836.3 1396.6 738.25 496.2 -242.05 539 1257.125 -718.125 | 657.9 730.5 890.8 1478.2 2161.5 1846.8 2274.3 1949.2 1662.5 1018.2 -644.3 939.35 2057.95 -1118.6 | 708.1 553.5 484.8 673.4 919.2 1752.5 1455 1110 813.65 698.7 -114.95 604.95 1309.175 -704.225 | 508.6 963.8 745.3 642.2 1460.3 1253.1 1472.4 1367.2 1108.45 522.8 -585.65 714.975 1388.25 -673.275 | 4103.5 2495.1 3504.5 2453.1 1374.7 1114.9 1231.2 1311.9 1913.9 3439.2 1525.3 3139.05 1258.175 1880.875 | 7571.2 10854.5 10304.2 8012.7 5454.1 2481.6 3431.4 2819.9 6512.65 6894.9 382.25 9185.65 3546.75 5638.9 | 3893.3 4182.7 5365.8 2728.2 1524 1132.9 1102 1757.6 2242.9 3176.2 933.3 4042.5 1379.125 2663.375 | 4635.3 1516.9 4523.9 2784.2 1137 1678.9 1497.5 770.6 1597.9 5390.5 3792.6 3365.075 1271 2094.075 | 10756.1 4475.7 4207.6 3860.3 2043.6 1351.5 1300.5 2171.3 3015.8 7375.7 4359.9 5824.925 1716.725 4108.2 |
| Whether meet | Be | Be | Be | Be | Be | Be | Be | Be | Be | Be |
In the table 24: coincidence rate is 10/10.Infer that tested sample is carcinoma of the pancreas patient's PBMC.
Embodiment 25
Operation is with reference to embodiment 1, and the result is referring to table 25.
Table 25 cross validation 12-2
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median | T1 T2 T4 T5 N1 N3 N4 N5 | 6615.2 11386.6 5007.4 6973.1 21113.1 13886.1 16847.6 17733.3 12636.35 | 340.3 658.7 453.5 703.5 773 1022.6 1836.3 1396.6 738.25 | 657.9 730.5 890.8 1478.2 2161.5 1846.8 2274.3 1949.2 1662.5 | 708.1 553.5 484.8 673.4 919.2 1752.5 1455 1110 813.65 | 508.6 963.8 745.3 642.2 1460.3 1253.1 1472.4 1367.2 1108.45 | 4103.5 2495.1 3504.5 2453.1 1374.7 1114.9 1231.2 1311.9 1913.9 | 7571.2 10854.5 10304.2 8012.7 5454.1 2481.6 3431.4 2819.9 6512.65 | 3893.3 4182.7 5365.8 2728.2 1524 1132.9 1102 1757.6 2242.9 | 4635.3 1516.9 4523.9 2784.2 1137 1678.9 1497.5 770.6 1597.9 | 10756.1 4475.7 4207.6 3860.3 2043.6 1351.5 1300.5 2171.3 3015.8 |
| Test group differs from 1 T mean N difference in means 2 | N2 | 10817.5 -1818.85 7495.575 17395.025 -9899.45 | 782.5 44.25 539 1257.125 -718.125 | 1772.8 110.3 939.35 2057.95 -1118.6 | 1117.8 304.15 604.95 1309.175 -704.225 | 1194.4 85.95 714.975 1388.25 -673.275 | 2041.6 127.7 3139.05 1258.175 1880.875 | 3179.9 -3332.75 9185.65 3546.75 5638.9 | 1808 -434.9 4042.5 1379.125 2663.375 | 1649.9 52 3365.075 1271 2094.075 | 2940 -75.8 5824.925 1716.725 4108.2 |
| Whether meet | Be | Not | Not | Not | Not | Be | Not | Not | Be | Not |
In the table 25: the rate of not meeting is 7/10.Infer the PBMC of tested sample for the normal people.
Embodiment 26
Operation is with reference to embodiment 1, and the result is referring to table 26.
Table 26. cross validation 13-1
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T1 T2 T4 T5 N1 N2 N4 N5 T3 | 6615.2 11386.6 5007.4 6973.1 21113.1 10817.5 16847.6 17733.3 11102.05 5944.1 -5157.95 7495.575 16627.875 -9132.3 | 340.3 658.7 453.5 703.5 773 782.5 1836.3 1396.6 738.25 496.2 -242.05 539 1197.1 -658.1 | 657.9 730.5 890.8 1478.2 2161.5 1772.8 2274.3 1949.2 1625.5 1018.2 -607.3 939.35 2039.45 -1100.1 | 708.1 553.5 484.8 673.4 919.2 1117.8 1455 1110 813.65 698.7 -114.95 604.95 1150.5 -545.55 | 508.6 963.8 745.3 642.2 1460.3 1194.4 1472.4 1367.2 1079.1 522.8 -556.3 714.975 1373.575 -658.6 | 4103.5 2495.1 3504.5 2453.1 1374.7 2041.6 1231.2 1311.9 2247.35 3439.2 1191.85 3139.05 1489.85 1649.2 | 7571.2 10854.5 10304.2 8012.7 5454.1 3179.9 3431.4 2819.9 6512.65 6894.9 382.25 9185.65 3721.325 5464.325 | 3893.3 4182.7 5365.8 2728.2 1524 1808 1102 1757.6 2268.1 3176.2 908.1 4042.5 1547.9 2494.6 | 4635.3 1516.9 4523.9 2784.2 1137 1649.9 1497.5 770.6 1583.4 5390.5 3807.1 3365.075 1263.75 2101.325 | 10756.1 4475.7 4207.6 3860.3 2043.6 2940 1300.5 2171.3 3400.15 7375.7 3975.55 5824.925 2113.85 3711.075 |
| Whether meet | Be | Be | Be | Be | Be | Be | Be | Be | Be | Be |
In the table 26: coincidence rate is 10/10.Infer that tested sample is carcinoma of the pancreas patient's PBMC.
Embodiment 27
Operation is with reference to embodiment 1, and the result is referring to table 27.
Table 27. cross validation 13-2
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| The training group | T1 T2 T4 | 6615.2 11386.6 5007.4 | 340.3 658.7 453.5 | 657.9 730.5 890.8 | 708.1 553.5 484.8 | 508.6 963.8 745.3 | 4103.5 2495.1 3504.5 | 7571.2 10854.5 10304.2 | 3893.3 4182.7 5365.8 | 4635.3 1516.9 4523.9 | 10756.1 4475.7 4207.6 |
| The median test group differs from 1 T mean N difference in means 2 | T5 N1 N2 N4 N5 N3 | 6973.1 21113.1 10817.5 16847.6 17733.3 11102.05 13886.1 2784.05 7495.575 16627.875 -9132.3 | 703.5 773 782.5 1836.3 1396.6 738.25 1022.6 284.35 539 1197.1 -658.1 | 1478.2 2161.5 1772.8 2274.3 1949.2 1625.5 1846.8 221.3 939.35 2039.45 -1100.1 | 673.4 919.2 1117.8 1455 1110 813.65 1752.5 938.85 604.95 1150.5 -545.55 | 642.2 1460.3 1194.4 1472.4 1367.2 1079.1 1253.1 174 714.975 1373.575 -658.6 | 2453.1 1374.7 2041.6 1231.2 1311.9 2247.35 1114.9 -1132.45 3139.05 1489.85 1649.2 | 8012.7 5454.1 3179.9 3431.4 2819.9 6512.65 2481.6 -4031.05 9185.65 3721.325 5464.325 | 2728.2 1524 1808 1102 1757.6 2268.1 1132.9 -1135.2 4042.5 1547.9 2494.6 | 2784.2 1137 1649.9 1497.5 770.6 1583.4 1678.9 95.5 3365.075 1263.75 2101.325 | 3860.3 2043.6 2940 1300.5 2171.3 3400.15 1351.5 -2048.65 5824.925 2113.85 3711.075 |
| Whether meet | Not | Not | Not | Not | Not | Not | Not | Not | Be | Not |
In the table 27: the rate of not meeting is 9/10.Infer the PBMC of tested sample for the normal people.
Embodiment 28
Operation is with reference to embodiment 1, and the result is referring to table 28.
Table 28 cross validation 14-1
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T1 T2 T4 T5 N1 N2 N3 N5 T3 | 6615.2 11386.6 5007.4 6973.1 21113.1 10817.5 13886.1 17733.3 11102.05 5944.1 -5157.95 7495.575 15887.5 -8391.925 | 340.3 658.7 453.5 703.5 773 782.5 1022.6 1396.6 738.25 496.2 -242.05 539 993.675 -454.675 | 657.9 730.5 890.8 1478.2 2161.5 1772.8 1846.8 1949.2 1625.5 1018.2 -607.3 939.35 1932.575 -993.225 | 708.1 553.5 484.8 673.4 919.2 1117.8 1752.5 1110 813.65 698.7 -114.95 604.95 1224.875 -619.925 | 508.6 963.8 745.3 642.2 1460.3 1194.4 1253.1 1367.2 1079.1 522.8 -556.3 714.975 1318.75 -603.775 | 4103.5 2495.1 3504.5 2453.1 1374.7 2041.6 1114.9 1311.9 2247.35 3439.2 1191.85 3139.05 1460.775 1678.275 | 7571.2 10854.5 10304.2 8012.7 5454.1 3179.9 2481.6 2819.9 6512.65 6894.9 382.25 9185.65 3483.875 5701.775 | 3893.3 4182.7 5365.8 2728.2 1524 1808 1132.9 1757.6 2268.1 3176.2 908.1 4042.5 1555.625 2486.875 | 4635.3 1516.9 4523.9 2784.2 1137 1649.9 1678.9 770.6 1664.4 5390.5 3726.1 3365.075 1309.1 2055.975 | 10756.1 4475.7 4207.6 3860.3 2043.6 2940 1351.5 2171.3 3400.15 7375.7 3975.55 5824.925 2126.6 3698.325 |
| Whether meet | Be | Be | Be | Be | Be | Be | Be | Be | Be | Be |
In the table 28: coincidence rate is 10/10.Infer that tested sample is carcinoma of the pancreas patient's PBMC.
Embodiment 29 operations are with reference to embodiment 1, and the result is referring to table 29.
Table 29. cross validation 14-2
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T1 T2 T4 T5 N1 N2 N3 N5 N4 | 6615.2 11386.6 5007.4 6973.1 21113.1 10817.5 13886.1 17733.3 11102.05 16847.6 5745.55 7495.575 15887.5 -8391.925 | 340.3 658.7 453.5 703.5 773 782.5 1022.6 1396.6 738.25 1836.3 1098.05 539 993.675 -454.675 | 657.9 730.5 890.8 1478.2 2161.5 1772.8 1846.8 1949.2 1625.5 2274.3 648.8 939.35 1932.575 -993.225 | 708.1 553.5 484.8 673.4 919.2 1117.8 1752.5 1110 813.65 1455 641.35 604.95 1224.875 -619.925 | 508.6 963.8 745.3 642.2 1460.3 1194.4 1253.1 1367.2 1079.1 1472.4 393.3 714.975 1318.75 -603.775 | 4103.5 2495.1 3504.5 2453.1 1374.7 2041.6 1114.9 1311.9 2247.35 1231.2 -1016.15 3139.05 1460.775 1678.275 | 7571.2 10854.5 10304.2 8012.7 5454.1 3179.9 2481.6 2819.9 6512.65 3431.4 -3081.25 9185.65 3483.875 5701.775 | 3893.3 4182.7 5365.8 2728.2 1524 1808 1132.9 1757.6 2268.1 1102 -1166.1 4042.5 1555.625 2486.875 | 4635.3 1516.9 4523.9 2784.2 1137 1649.9 1678.9 770.6 1664.4 1497.5 -166.9 3365.075 1309.1 2055.975 | 10756.1 4475.7 4207.6 3860.3 2043.6 2940 1351.5 2171.3 3400.15 1300.5 -2099.65 5824.925 2126.6 3698.325 |
| Whether meet | Not | Not | Not | Not | Not | Not | Not | Not | Not | Not |
In the table 29: the rate of not meeting is 10/10.Infer the PBMC of tested sample for the normal people.
Embodiment 30
Operation is with reference to embodiment 1, and the result is referring to table 30.
Table 30 cross validation 15-1
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean | T1 T2 T4 T5 N1 N2 N3 N4 T3 | 6615.2 11386.6 5007.4 6973.1 21113.1 10817.5 13886.1 16847.6 11102.05 5944.1 -5157.95 7495.575 | 340.3 658.7 453.5 703.5 773 782.5 1022.6 1836.3 738.25 496.2 -242.05 539 | 657.9 730.5 890.8 1478.2 2161.5 1772.8 1846.8 2274.3 1625.5 1018.2 -607.3 939.35 | 708.1 553.5 484.8 673.4 919.2 1117.8 1752.5 1455 813.65 698.7 -114.95 604.95 | 508.6 963.8 745.3 642.2 1460.3 1194.4 1253.1 1472.4 1079.1 522.8 -556.3 714.975 | 4103.5 2495.1 3504.5 2453.1 1374.7 2041.6 1114.9 1231.2 2247.35 3439.2 1191.85 3139.05 | 7571.2 10854.5 10304.2 8012.7 5454.1 3179.9 2481.6 3431.4 6512.65 6894.9 382.25 9185.65 | 3893.3 4182.7 5365.8 2728.2 1524 1808 1132.9 1102 2268.1 3176.2 908.1 4042.5 | 4635.3 1516.9 4523.9 2784.2 1137 1649.9 1678.9 1497.5 1664.4 5390.5 3726.1 3365.075 | 10756.1 4475.7 4207.6 3860.3 2043.6 2940 1351.5 1300.5 3400.15 7375.7 3975.55 5824.925 |
| N difference in means 2 | 15666.075 -8170.5 | 1103.6 -564.6 | 2013.85 -1074.5 | 1311.125 -706.175 | 1345.05 -630.075 | 1440.6 1698.45 | 3636.75 5548.9 | 1391.725 2650.775 | 1490.825 1874.25 | 1908.9 3916.025 | |
| Whether meet | Be | Be | Be | Be | Be | Be | Be | Be | Be | Be |
In the table 30: coincidence rate is 10/10.Infer that tested sample is carcinoma of the pancreas patient's PBMC.
Embodiment 31
Operation is with reference to embodiment 1, and the result is referring to table 31.
Table 31. cross validation 15-2
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T1 T2 T4 T5 N1 N2 N3 N4 N5 | 6615.2 11386.6 5007.4 6973.1 21113.1 10817.5 13886.1 16847.6 11102.05 17733.3 6631.25 7495.575 15666.075 -8170.5 | 340.3 658.7 453.5 703.5 773 782.5 1022.6 1836.3 738.25 1396.6 658.35 539 1103.6 -564.6 | 657.9 730.5 890.8 1478.2 2161.5 1772.8 1846.8 2274.3 1625.5 1949.2 323.7 939.35 2013.85 -1074.5 | 708.1 553.5 484.8 673.4 919.2 1117.8 1752.5 1455 813.65 1110 296.35 604.95 1311.125 -706.175 | 508.6 963.8 745.3 642.2 1460.3 1194.4 1253.1 1472.4 1079.1 1367.2 288.1 714.975 1345.05 -630.075 | 4103.5 2495.1 3504.5 2453.1 1374.7 2041.6 1114.9 1231.2 2247.35 1311.9 935.45 3139.05 1440.6 1698.45 | 7571.2 10854.5 10304.2 8012.7 5454.1 3179.9 2481.6 3431.4 6512.65 2819.9 -3692.75 9185.65 3636.75 5548.9 | 3893.3 4182.7 5365.8 2728.2 1524 1808 1132.9 1102 2268.1 1757.6 -510.5 4042.5 1391.725 2650.775 | 4635.3 1516.9 4523.9 2784.2 1137 1649.9 1678.9 1497.5 1664.4 770.6 -893.8 3365.075 1490.825 1874.25 | 10756.1 4475.7 4207.6 3860.3 2043.6 2940 1351.5 1300.5 3400.15 2171.3 -1228.85 5824.925 1908.9 3916.025 |
| Whether meet | Not | Not | Not | Not | Not | Not | Not | Not | Not | Not |
In the table 31: the rate of not meeting is 10/10.Infer the PBMC of tested sample for the normal people.
Embodiment 32
Operation is with reference to embodiment 1, and the result is referring to table 32.
Table 32 cross validation 16-1
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| The training group | T1 T2 T3 T5 N2 N3 | 6615.2 11386.6 5944.1 6973.1 10817.5 13886.1 | 340.3 658.7 496.2 703.5 782.5 1022.6 | 657.9 730.5 1018.2 1478.2 1772.8 1846.8 | 708.1 553.5 698.7 673.4 1117.8 1752.5 | 508.6 963.8 522.8 642.2 1194.4 1253.1 | 4103.5 2495.1 3439.2 2453.1 2041.6 1114.9 | 7571.2 10854.5 6894.9 8012.7 3179.9 2481.6 | 3893.3 4182.7 3176.2 2728.2 1808 1132.9 | 4635.3 1516.9 5390.5 2784.2 1649.9 1678.9 | 10756.1 4475.7 7375.7 3860.3 2940 1351.5 |
| The median test group differs from 1 T mean N difference in means 2 | N4 N5 T4 | 16847.6 17733.3 11102.05 5007.4 -6094.65 7729.75 14821.125 -7091.375 | 1836.3 1396.6 743 453.5 -289.5 549.675 1259.5 -709.825 | 2274.3 1949.2 1625.5 890.8 -734.7 971.2 1960.775 -989.575 | 1455 1110 909.05 484.8 -424.25 658.425 1358.825 -700.4 | 1472.4 1367.2 1079.1 745.3 -333.8 659.35 1321.775 -662.425 | 1231.2 1311.9 2247.35 3504.5 1257.15 3122.725 1424.9 1697.825 | 3431.4 2819.9 5163.15 10304.2 5141.05 8333.325 2978.2 5355.125 | 1102 1757.6 2268.1 5365.8 3097.7 3495.1 1450.125 2044.975 | 1497.5 770.6 1664.4 4523.9 2859.5 3581.725 1399.225 2182.5 | 1300.5 2171.3 3400.15 4207.6 807.45 6616.95 1940.825 4676.125 |
| Whether meet | Be | Be | Be | Be | Be | Be | Be | Be | Be | Be |
In the table 32: coincidence rate is 10/10.Infer that tested sample is carcinoma of the pancreas patient's PBMC.
Embodiment 33
Operation is with reference to embodiment 1, and the result is referring to table 33.
Table 33 cross validation 16-2
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T1 T2 T3 T5 N2 N3 N4 N5 N1 | 6615.2 11386.6 5944.1 6973.1 10817.5 13886.1 16847.6 17733.3 11102.05 21113.1 10011.05 7729.75 14821.125 -7091.375 | 340.3 658.7 496.2 703.5 782.5 1022.6 1836.3 1396.6 743 773 30 549.675 1259.5 -709.825 | 657.9 730.5 1018.2 1478.2 1772.8 1846.8 2274.3 1949.2 1625.5 2161.5 536 971.2 1960.775 -989.575 | 708.1 553.5 698.7 673.4 1117.8 1752.5 1455 1110 909.05 919.2 10.15 658.425 1358.825 -700.4 | 508.6 963.8 522.8 642.2 1194.4 1253.1 1472.4 1367.2 1079.1 1460.3 381.2 659.35 1321.775 -662.425 | 4103.5 2495.1 3439.2 2453.1 2041.6 1114.9 1231.2 1311.9 2247.35 1374.7 -872.65 3122.725 1424.9 1697.825 | 7571.2 10854.5 6894.9 8012.7 3179.9 2481.6 3431.4 2819.9 5163.15 5454.1 290.95 8333.325 2978.2 5355.125 | 3893.3 4182.7 3176.2 2728.2 1808 1132.9 1102 1757.6 2268.1 1524 -744.1 3495.1 1450.125 2044.975 | 4635.3 1516.9 5390.5 2784.2 1649.9 1678.9 1497.5 770.6 1664.4 1137 -527.4 3581.725 1399.225 2182.5 | 10756.1 4475.7 7375.7 3860.3 2940 1351.5 1300.5 2171.3 3400.15 2043.6 -1356.55 6616.95 1940.825 4676.125 |
| Whether meet | Not | Not | Not | Not | Not | Not | Be | Not | Not | Not |
In the table 33: the rate of not meeting is 9/10.Infer the PBMC of tested sample for the normal people.
Embodiment 34
Operation is with reference to embodiment 1, and the result is referring to table 34.
Table 34. cross validation 17-1
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 |
| Training group median test group differs from 1 T mean N difference in means 2 | T1 T2 T3 T5 N1 N3 N4 N5 T4 | 6615.2 11386.6 5944.1 6973.1 21113.1 13886.1 16847.6 17733.3 12636.35 5007.4 -7628.95 7729.75 17395.025 -9665.275 | 340.3 658.7 496.2 703.5 773 1022.6 1836.3 1396.6 738.25 453.5 -284.75 549.675 1257.125 -707.45 | 657.9 730.5 1018.2 1478.2 2161.5 1846.8 2274.3 1949.2 1662.5 890.8 -771.7 971.2 2057.95 -1086.75 | 708.1 553.5 698.7 673.4 919.2 1752.5 1455 1110 813.65 484.8 -328.85 658.425 1309.175 -650.75 | 508.6 963.8 522.8 642.2 1460.3 1253.1 1472.4 1367.2 1108.45 745.3 -363.15 659.35 1388.25 -728.9 | 4103.5 2495.1 3439.2 2453.1 1374.7 1114.9 1231.2 1311.9 1913.9 3504.5 1590.6 3122.725 1258.175 1864.55 | 7571.2 10854.5 6894.9 8012.7 5454.1 2481.6 3431.4 2819.9 6174.5 10304.2 4129.7 8333.325 3546.75 4786.575 | 3893.3 4182.7 3176.2 2728.2 1524 1132.9 1102 1757.6 2242.9 5365.8 3122.9 3495.1 1379.125 2115.975 | 4635.3 1516.9 5390.5 2784.2 1137 1678.9 1497.5 770.6 1597.9 4523.9 2926 3581.725 1271 2310.725 | 10756.1 4475.7 7375.7 3860.3 2043.6 1351.5 1300.5 2171.3 3015.8 4207.6 1191.8 6616.95 1716.725 4900.225 |
| Whether meet | Be | Be | Be | Be | Be | Be | Be | Be | Be | Be |
In the table 34: coincidence rate is 10/10.Infer that tested sample is carcinoma of the pancreas patient's PBMC.
Embodiment 35
Operation is with reference to embodiment 1, and the result is referring to table 35.
Table 35. cross validation 17-2
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T1 T2 T3 T5 N1 N3 N4 N5 N2 | 6615.2 11386.6 5944.1 6973.1 21113.1 13886.1 16847.6 17733.3 12636.35 10817.5 -1818.85 7729.75 17395.025 -9665.275 | 340.3 658.7 496.2 703.5 773 1022.6 1836.3 1396.6 738.25 782.5 44.25 549.675 1257.125 -707.45 | 657.9 730.5 1018.2 1478.2 2161.5 1846.8 2274.3 1949.2 1662.5 1772.8 110.3 971.2 2057.95 -1086.75 | 708.1 553.5 698.7 673.4 919.2 1752.5 1455 1110 813.65 1117.8 304.15 658.425 1309.175 -650.75 | 508.6 963.8 522.8 642.2 1460.3 1253.1 1472.4 1367.2 1108.45 1194.4 85.95 659.35 1388.25 -728.9 | 4103.5 2495.1 3439.2 2453.1 1374.7 1114.9 1231.2 1311.9 1913.9 2041.6 127.7 3122.725 1258.175 1864.55 | 7571.2 10854.5 6894.9 8012.7 5454.1 2481.6 3431.4 2819.9 6174.5 3179.9 -2994.6 8333.325 3546.75 4786.575 | 3893.3 4182.7 3176.2 2728.2 1524 1132.9 1102 1757.6 2242.9 1808 -434.9 3495.1 1379.125 2115.975 | 4635.3 1516.9 5390.5 2784.2 1137 1678.9 1497.5 770.6 1597.9 1649.9 52 3581.725 1271 2310.725 | 10756.1 4475.7 7375.7 3860.3 2043.6 1351.5 1300.5 2171.3 3015.8 2940 -75.8 6616.95 1716.725 4900.225 |
| Whether meet | Be | Not | Not | Not | Not | Be | Not | Not | Be | Not |
In the table 35: coincidence rate is 7/10.Infer the PBMC of tested sample for the normal people.
Embodiment 36
Operation is with reference to embodiment 1, and the result is referring to table 36.
Table 36. cross validation 18-1
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T1 T2 T3 T5 N1 N2 N4 N5 T4 | 6615.2 11386.6 5944.1 6973.1 21113.1 10817.5 16847.6 17733.3 11102.05 5007.4 -6094.65 7729.75 16627.875 -8898.125 | 340.3 658.7 496.2 703.5 773 782.5 1836.3 1396.6 738.25 453.5 -284.75 549.675 1197.1 -647.425 | 657.9 730.5 1018.2 1478.2 2161.5 1772.8 2274.3 1949.2 1625.5 890.8 -734.7 971.2 2039.45 -1068.25 | 708.1 553.5 698.7 673.4 919.2 1117.8 1455 1110 813.65 484.8 -328.85 658.425 1150.5 -492.075 | 508.6 963.8 522.8 642.2 1460.3 1194.4 1472.4 1367.2 1079.1 745.3 -333.8 659.35 1373.575 -714.225 | 4103.5 2495.1 3439.2 2453.1 1374.7 2041.6 1231.2 1311.9 2247.35 3504.5 1257.15 3122.725 1489.85 1632.875 | 7571.2 10854.5 6894.9 8012.7 5454.1 3179.9 3431.4 2819.9 6174.5 10304.2 4129.7 8333.325 3721.325 4612 | 3893.3 4182.7 3176.2 2728.2 1524 1808 1102 1757.6 2268.1 5365.8 3097.7 3495.1 1547.9 1947.2 | 4635.3 1516.9 5390.5 2784.2 1137 1649.9 1497.5 770.6 1583.4 4523.9 2940.5 3581.725 1263.75 2317.975 | 10756.1 4475.7 7375.7 3860.3 2043.6 2940 1300.5 2171.3 3400.15 4207.6 807.45 6616.95 2113.85 4503.1 |
| Whether meet | Be | Be | Be | Be | Be | Be | Be | Be | Be | Be |
In the table 36: coincidence rate is 10/10.Infer that tested sample is carcinoma of the pancreas patient's PBMC.
Embodiment 37
Operation is with reference to embodiment 1, and the result is referring to table 37.
Table 37 cross validation 18-2
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| The training group | T1 T2 T3 T5 N1 N2 N4 N5 | 6615.2 11386.6 5944.1 6973.1 21113.1 10817.5 16847.6 17733.3 | 340.3 658.7 496.2 703.5 773 782.5 1836.3 1396.6 | 657.9 730.5 1018.2 1478.2 2161.5 1772.8 2274.3 1949.2 | 708.1 553.5 698.7 673.4 919.2 1117.8 1455 1110 | 508.6 963.8 522.8 642.2 1460.3 1194.4 1472.4 1367.2 | 4103.5 2495.1 3439.2 2453.1 1374.7 2041.6 1231.2 1311.9 | 7571.2 10854.5 6894.9 8012.7 5454.1 3179.9 3431.4 2819.9 | 3893.3 4182.7 3176.2 2728.2 1524 1808 1102 1757.6 | 4635.3 1516.9 5390.5 2784.2 1137 1649.9 1497.5 770.6 | 10756.1 4475.7 7375.7 3860.3 2043.6 2940 1300.5 2171.3 |
| The median test group differs from 1 T mean N difference in means 2 | N3 | 11102.05 13886.1 2784.05 7729.75 16627.875 -8898.125 | 738.25 1022.6 284.35 549.675 1197.1 -647.425 | 1625.5 1846.8 221.3 971.2 2039.45 -1068.25 | 813.65 1752.5 938.85 658.425 1150.5 -492.075 | 1079.1 1253.1 174 659.35 1373.575 -714.225 | 2247.35 1114.9 -1132.45 3122.725 1489.85 1632.875 | 6174.5 2481.6 -3692.9 8333.325 3721.325 4612 | 2268.1 1132.9 -1135.2 3495.1 1547.9 1947.2 | 1583.4 1678.9 95.5 3581.725 1263.75 2317.975 | 3400.15 13515 -2048.65 6616.95 2113.85 4503.1 |
| Whether meet | Not | Not | Not | Not | Not | Not | Not | Not | Be | Not |
In the table 37: the rate of not meeting is 9/10.Infer the PBMC of tested sample for the normal people.
Embodiment 38
Operation is with reference to embodiment 1, and the result is referring to table 38.
Table 38. cross validation 19-1
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T1 T2 T3 T5 N1 N2 N3 N5 T4 | 6615.2 11386.6 5944.1 6973.1 21113.1 10817.5 13886.1 17733.3 11102.05 5007.4 -6094.65 7729.75 15887.5 -8157.75 | 340.3 658.7 496.2 703.5 773 782.5 1022.6 1396.6 738.25 453.5 -284.75 49.675 993.675 -444 | 657.9 730.5 1018.2 1478.2 2161.5 1772.8 1846.8 1949.2 1625.5 890.8 -734.7 971.2 1932.575 -961.375 | 708.1 553.5 698.7 673.4 919.2 1117.8 1752.5 1110 813.65 484.8 -328.85 658.425 1224.875 -566.45 | 508.6 963.8 522.8 642.2 1460.3 1194.4 1253.1 1367.2 1079.1 745.3 -333.8 659.35 1318.75 -659.4 | 4103.5 2495.1 3439.2 2453.1 1374.7 2041.6 1114.9 1311.9 2247.35 3504.5 1257.15 3122.725 1460.775 1661.95 | 7571.2 10854.5 6894.9 8012.7 5454.1 3179.9 2481.6 2819.9 6174.5 10304.2 4129.7 8333.325 3483.875 4849.45 | 3893.3 4182.7 3176.2 2728.2 1524 1808 1132.9 1757.6 2268.1 5365.8 3097.7 3495.1 1555.625 1939.475 | 4635.3 1516.9 5390.5 2784.2 1137 1649.9 1678.9 770.6 1664.4 4523.9 2859.5 3581.725 1309.1 2272.625 | 10756.1 4475.7 7375.7 3860.3 2043.6 2940 1351.5 2171.3 3400.15 4207.6 807.45 6616.95 2126.6 4490.35 |
| Whether meet | Be | Be | Be | Be | Be | Be | Be | Be | Be | Be |
In the table 38: coincidence rate is 10/10.Infer that tested sample is carcinoma of the pancreas patient's PBMC.
Embodiment 39
Operation is with reference to embodiment 1, and the result is referring to table 39.
Table 39. cross validation 19-2
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| The training group | T1 T2 | 6615.2 11386.6 | 340.3 658.7 | 657.9 730.5 | 708.1 553.5 | 508.6 963.8 | 4103.5 2495.1 | 7571.2 10854.5 | 3893.3 4182.7 | 4635.3 1516.9 | 10756.1 4475.7 |
| The median test group differs from 1 T mean N difference in means 2 | T3 T5 N1 N2 N3 N5 N4 | 5944.1 6973.1 21113.1 10817.5 13886.1 17733.3 11102.05 16847.6 5745.55 7729.75 15887.5 -8157.75 | 496.2 703.5 773 782.5 1022.6 1396.6 738.25 1836.3 1098.05 549.675 993.675 -444 | 1018.2 1478.2 2161.5 1772.8 1846.8 1949.2 1625.5 2274.3 648.8 971.2 1932.575 -961.375 | 698.7 673.4 919.2 1117.8 1752.5 1110 813.65 1455 641.35 658.425 1224.875 -566.45 | 522.8 642.2 1460.3 1194.4 1253.1 1367.2 1079.1 1472.4 393.3 659.35 1318.75 -659.4 | 3439.2 2453.1 1374.7 2041.6 1114.9 1311.9 2247.35 1231.2 -1016.15 3122.725 1460.775 1661.95 | 6894.9 8012.7 5454.1 3179.9 2481.6 2819.9 6174.5 3431.4 -2743.1 8333.325 3483.875 4849.45 | 3176.2 2728.2 1524 1808 1132.9 1757.6 2268.1 1102 -1166.1 3495.1 1555.625 1939.475 | 5390.5 2784.2 1137 1649.9 1678.9 770.6 1664.4 1497.5 -166.9 3581.725 1309.1 2272.625 | 7375.7 3860.3 2043.6 2940 1351.5 2171.3 3400.15 1300.5 -2099.65 6616.95 2126.6 4490.35 |
| Whether meet | Not | Not | Not | Not | Not | Not | Not | Not | Not | Not |
In the table 39: the rate of not meeting is 10/10.Infer the PBMC of tested sample for the normal people.
Embodiment 40
Operation is with reference to embodiment 1, and the result is referring to table 40.
Table 40. cross validation 20-1
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T1 T2 T3 T5 N1 N2 N3 N4 T4 | 6615.2 11386.6 5944.1 6973.1 21113.1 10817.5 13886.1 16847.6 11102.05 5007.4 -6094.65 7729.75 15666.075 -7936.325 | 340.3 658.7 496.2 703.5 773 782.5 1022.6 1836.3 738.25 453.5 -284.75 549.675 1103.6 -553.925 | 657.9 730.5 1018.2 1478.2 2161.5 1772.8 1846.8 2274.3 1625.5 890.8 -734.7 971.2 2013.85 -1042.65 | 708.1 553.5 698.7 673.4 919.2 1117.8 1752.5 1455 813.65 484.8 -328.85 658.425 311.125 -652.7 | 508.6 963.8 522.8 642.2 1460.3 1194.4 1253.1 1472.4 1079.1 745.3 -333.8 659.35 1345.05 -685.7 | 4103.5 2495.1 3439.2 2453.1 1374.7 2041.6 1114.9 1231.2 2247.35 3504.5 1257.15 3122.725 1440.6 1682.125 | 7571.2 10854.5 6894.9 8012.7 5454.1 3179.9 2481.6 3431.4 6174.5 10304.2 4129.7 8333.325 3636.75 4696.575 | 3893.3 4182.7 3176.2 2728.2 1524 1808 1132.9 1102 2268.1 5365.8 3097.7 3495.1 1391.725 2103.375 | 4635.3 1516.9 5390.5 2784.2 1137 1649.9 1678.9 1497.5 1664.4 4523.9 2859.5 3581.725 1490.825 2090.9 | 10756.1 4475.7 7375.7 3860.3 2043.6 2940 1351.5 1300.5 3400.15 4207.6 807.45 6616.95 1908.9 4708.05 |
| Whether meet | Be | Be | Be | Be | Be | Be | Be | Be | Be | Be |
In the table 40: coincidence rate is 10/10.Infer that tested sample is carcinoma of the pancreas patient's PBMC.
Embodiment 41
Operation is with reference to embodiment 1, and the result is referring to table 41.
Table 41. cross validation 20-2
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T1 T2 T3 T5 N1 N2 N3 N4 N5 | 6615.2 11386.6 5944.1 6973.1 21113.1 10817.5 13886.1 16847.6 11102.05 17733.3 6631.25 7729.75 15666.075 -7936.325 | 340.3 658.7 496.2 703.5 773 782.5 1022.6 1836.3 738.25 1396.6 658.35 549.675 1103.6 -553.925 | 657.9 730.5 1018.2 1478.2 2161.5 1772.8 1846.8 2274.3 1625.5 1949.2 323.7 971.2 2013.85 -1042.65 | 708.1 553.5 698.7 673.4 919.2 1117.8 1752.5 1455 813.65 1110 296.35 658.425 1311.125 -652.7 | 508.6 963.8 522.8 642.2 1460.3 1194.4 1253.1 1472.4 1079.1 1367.2 288.1 659.35 1345.05 -685.7 | 4103.5 2495.1 3439.2 2453.1 1374.7 2041.6 1114.9 1231.2 2247.35 1311.9 -935.45 3122.725 1440.6 1682.125 | 7571.2 10854.5 6894.9 8012.7 5454.1 3179.9 2481.6 3431.4 6174.5 2819.9 -3354.6 8333.325 3636.75 4696.575 | 3893.3 4182.7 3176.2 2728.2 1524 1808 1132.9 1102 2268.1 1757.6 -510.5 3495.1 1391.725 2103.375 | 4635.3 1516.9 5390.5 2784.2 1137 1649.9 1678.9 1497.5 1664.4 770.6 -893.8 3581.725 1490.825 2090.9 | 10756.1 4475.7 7375.7 3860.3 2043.6 2940 1351.5 1300.5 3400.15 2171.3 -1228.85 6616.95 1908.9 4708.05 |
| Whether meet | Not | Not | Not | Not | Not | Not | Not | Not | Not | Not |
In the table 41: the rate of not meeting is 10/10.Infer the PBMC of tested sample for the normal people.
Embodiment 42
Operation is with reference to embodiment 1, and the result is referring to table 42.
Table 42. cross validation 21-1
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 | T1 T2 T3 T4 N2 N3 N4 N5 T5 | 6615.2 11386.6 5944.1 5007.4 10817.5 13886.1 16847.6 17733.3 11102.05 6973.1 -4128.95 | 340.3 658.7 496.2 453.5 782.5 1022.6 1836.3 1396.6 720.6 703.5 -17.1 | 657.9 730.5 1018.2 890.8 1772.8 1846.8 2274.3 1949.2 1395.5 1478.2 82.7 | 708.1 553.5 698.7 484.8 1117.8 1752.5 1455 1110 909.05 673.4 235.65 | 508.6 963.8 522.8 745.3 1194.4 1253.1 1472.4 1367.2 1079.1 642.2 -436.9 | 4103.5 2495.1 3439.2 3504.5 2041.6 1114.9 1231.2 1311.9 2268.35 2453.1 184.75 | 7571.2 10854.5 6894.9 10304.2 3179.9 2481.6 3431.4 2819.9 5163.15 8012.7 2849.55 | 3893.3 4182.7 3176.2 5365.8 1808 1132.9 1102 1757.6 2492.1 2728.2 236.1 | 4635.3 1516.9 5390.5 4523.9 1649.9 1678.9 1497.5 770.6 1664.4 2784.2 1119.8 | 10756.1 4475.7 7375.7 4207.6 2940 1351.5 1300.5 2171.3 3573.8 3860.3 286.5 |
| T mean N difference in means 2 | 7238.325 14821.125 -7582.8 | 487.175 1259.5 -772.325 | 824.35 1960.775 -1136.425 | 611.275 1358.825 -747.55 | 685.125 1321.775 -636.65 | 3385.575 1424.9 1960.675 | 8906.2 2978.2 5928 | 4154.5 1450.125 2704.375 | 4016.65 1399.225 2617.425 | 6703.775 1940.825 4762.95 | |
| Whether meet | Be | Be | Not | Be | Be | Be | Be | Be | Be | Be |
In the table 42: coincidence rate is 9/10.Infer that tested sample is carcinoma of the pancreas patient's PBMC.
Embodiment 43
Operation is with reference to embodiment 1, and the result is referring to table 43.
Table 43. cross validation 21-2
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T1 T2 T3 T4 N2 N3 N4 N5 N1 | 6615.2 11386.6 5944.1 5007.4 10817.5 13886.1 16847.6 17733.3 11102.05 21113.1 10011.05 7238.325 14821.125 -7582.8 | 340.3 658.7 496.2 453.5 782.5 1022.6 1836.3 1396.6 720.6 773 52.4 487.175 1259.5 -772.325 | 657.9 730.5 1018.2 890.8 1772.8 1846.8 2274.3 1949.2 1395.5 2161.5 766 824.35 1960.775 -1136.425 | 708.1 553.5 698.7 484.8 1117.8 1752.5 1455 1110 909.05 919.2 10.15 611.275 1358.825 -747.55 | 508.6 963.8 522.8 745.3 1194.4 1253.1 1472.4 1367.2 1079.1 1460.3 381.2 685.125 1321.775 -636.65 | 4103.5 2495.1 3439.2 3504.5 2041.6 1114.9 1231.2 1311.9 2268.35 1374.7 -893.65 3385.575 1424.9 1960.675 | 7571.2 10854.5 6894.9 10304.2 3179.9 2481.6 3431.4 2819.9 5163.15 5454.1 290.95 8906.2 2978.2 5928 | 3893.3 4182.7 3176.2 5365.8 1808 1132.9 1102 1757.6 2492.1 1524 -968.1 4154.5 1450.125 2704.375 | 4635.3 1516.9 5390.5 4523.9 1649.9 1678.9 1497.5 770.6 1664.4 1137 -527.4 4016.65 1399.225 2617.425 | 10756.1 4475.7 7375.7 4207.6 2940 1351.5 1300.5 2171.3 3573.8 2043.6 -1530.2 6703.775 1940.825 4762.95 |
| Whether meet | Not | Not | Not | Not | Not | Not | Be | Not | Not | Not |
In the table 43: the rate of not meeting is 9/10.Infer the PBMC of tested sample for the normal people.
Embodiment 44
Operation is with reference to embodiment 1, and the result is referring to table 44.
Table 44. cross validation 22-1
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| The training group | T1 T2 T3 T4 N1 | 6615.2 11386.6 5944.1 5007.4 21113.1 | 340.3 658.7 496.2 453.5 773 | 657.9 730.5 1018.2 890.8 2161.5 | 708.1 553.5 698.7 484.8 919.2 | 508.6 963.8 522.8 745.3 1460.3 | 4103.5 2495.1 3439.2 3504.5 1374.7 | 7571.2 10854.5 6894.9 10304.2 5454.1 | 3893.3 4182.7 3176.2 5365.8 1524 | 4635.3 1516.9 5390.5 4523.9 1137 | 10756.1 4475.7 7375.7 4207.6 2043.6 |
| The median test group differs from 1 T mean N difference in means 2 | N3 N4 N5 T5 | 13886.1 16847.6 17733.3 12636.35 6973.1 -5663.25 7238.325 17395.025 -10156.7 | 1022.6 1836.3 1396.6 715.85 703.5 -12.35 487.175 1257.125 -769.95 | 1846.8 2274.3 1949.2 1432.5 1478.2 45.7 824.35 2057.95 -1233.6 | 1752.5 1455 1110 813.65 673.4 -140.25 611.275 1309.175 -697.9 | 1253.1 1472.4 1367.2 1108.45 642.2 -466.25 685.125 1388.25 -703.125 | 1114.9 1231.2 1311.9 1934.9 2453.1 518.2 3385.575 1258.175 2127.4 | 2481.6 3431.4 2819.9 6174.5 8012.7 1838.2 8906.2 3546.75 5359.45 | 1132.9 1102 1757.6 2466.9 2728.2 261.3 4154.5 1379.125 2775.375 | 1678.9 1497.5 770.6 1597.9 2784.2 1186.3 4016.65 1271 2745.65 | 1351.5 1300.5 2171.3 3189.45 3860.3 670.85 6703.775 1716.725 4987.05 |
| Whether meet | Be | Be | Not | Be | Be | Be | Be | Be | Be | Be |
In the table 44: coincidence rate is 9/10.Infer that tested sample is carcinoma of the pancreas patient's PBMC.
Embodiment 45
Operation is with reference to embodiment 1, and the result is referring to table 45.
Table 45. cross validation 22-2
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T1 T2 T3 T4 N1 N3 N4 N5 N2 | 6615.2 11386.6 5944.1 5007.4 21113.1 13886.1 16847.6 17733.3 12636.35 10817.5 -1818.85 7238.325 17395.025 -10156.7 | 340.3 658.7 496.2 453.5 773 1022.6 1836.3 1396.6 715.85 782.5 66.65 487.175 1257.125 -769.95 | 657.9 730.5 1018.2 890.8 2161.5 1846.8 2274.3 1949.2 1432.5 1772.8 340.3 824.35 2057.95 -1233.6 | 708.1 553.5 698.7 484.8 919.2 1752.5 1455 1110 813.65 1117.8 304.15 611.275 1309.175 -697.9 | 508.6 963.8 5228 745.3 1460.3 1253.1 1472.4 1367.2 1108.45 1194.4 85.95 685.125 1388.25 -703.125 | 4103.5 2495.1 3439.2 3504.5 1374.7 1114.9 1231.2 1311.9 1934.9 2041.6 106.7 3385.575 1258.175 2127.4 | 7571.2 10854.5 6894.9 10304.2 5454.1 2481.6 3431.4 2819.9 6174.5 3179.9 -2994.6 8906.2 3546.75 5359.45 | 3893.3 4182.7 3176.2 5365.8 1524 1132.9 1102 1757.6 2466.9 1808 -658.9 4154.5 1379.125 2775.375 | 4635.3 1516.9 5390.5 4523.9 1137 1678.9 1497.5 770.6 1597.9 1649.9 52 4016.65 1271 2745.65 | 10756.1 4475.7 7375.7 4207.6 2043.6 1351.5 1300.5 2171.3 3189.45 2940 -249.45 6703.775 1716.725 4987.05 |
| Whether meet | Be | Not | Not | Not | Not | Be | Not | Not | Be | Not |
In the table 45: the rate of not meeting is 7/10.Infer the PBMC of tested sample for the normal people.
Embodiment 46
Operation is with reference to embodiment 1, and the result is referring to table 46.
Table 46. cross validation 23-1
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T1 T2 T3 T4 N1 N2 N4 N5 T5 | 6615.2 11386.6 5944.1 5007.4 21113.1 10817.5 16847.6 17733.3 11102.05 6973.1 -4128.95 7238.325 16627.875 -9389.55 | 340.3 658.7 496.2 453.5 773 782.5 1836.3 1396.6 715.85 703.5 -12.35 487.175 1197.1 -709.925 | 657.9 730.5 1018.2 890.8 2161.5 1772.8 2274.3 1949.2 1395.5 1478.2 82.7 824.35 2039.45 -1215.1 | 708.1 553.5 698.7 484.8 919.2 1117.8 1455 1110 813.65 673.4 -140.25 611.275 1150.5 -539.225 | 508.6 963.8 522.8 745.3 1460.3 1194.4 1472.4 1367.2 1079.1 642.2 -436.9 685.125 1373.575 -688.45 | 4103.5 2495.1 3439.2 3504.5 1374.7 2041.6 1231.2 1311.9 2268.35 2453.1 184.75 3385.575 1489.85 1895.725 | 7571.2 10854.5 6894.9 10304.2 5454.1 3179.9 3431.4 2819.9 6174.5 8012.7 1838.2 8906.2 3721.325 5184.875 | 3893.3 4182.7 3176.2 5365.8 1524 1808 1102 1757.6 2492.1 2728.2 236.1 4154.5 1547.9 2606.6 | 4635.3 1516.9 5390.5 4523.9 1137 1649.9 1497.5 770.6 1583.4 2784.2 1200.8 4016.65 1263.75 2752.9 | 10756.1 4475.7 7375.7 4207.6 2043.6 2940 1300.5 2171.3 3573.8 3860.3 286.5 6703.775 2113.85 4589.925 |
| Whether meet | Be | Be | Not | Be | Be | Be | Be | Be | Be | Be |
In the table 46: coincidence rate is 9/10.Infer that tested sample is carcinoma of the pancreas patient's PBMC.
Embodiment 47
Operation is with reference to embodiment 1, and the result is referring to table 47.
Table 47. cross validation 23-2
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T1 T2 T3 T4 N1 N2 N4 N5 N3 | 6615.2 11386.6 5944.1 5007.4 21113.1 10817.5 16847.6 17733.3 11102.05 13886.1 2784.05 7238.325 16627.875 -9389.55 | 340.3 658.7 496.2 453.5 773 782.5 1836.3 1396.6 715.85 1022.6 306.75 487.175 1197.1 -709.925 | 657.9 730.5 1018.2 890.8 2161.5 1772.8 2274.3 1949.2 1395.5 1846.8 451.3 824.35 2039.45 -1215.1 | 708.1 553.5 698.7 484.8 919.2 1117.8 1455 1110 813.65 1752.5 938.85 611.275 1150.5 -539.225 | 508.6 963.8 522.8 745.3 1460.3 1194.4 1472.4 1367.2 1079.1 1253.1 174 685.125 1373.575 -688.45 | 4103.5 2495.1 3439.2 3504.5 1374.7 2041.6 1231.2 1311.9 2268.35 1114.9 -1153.45 3385.575 1489.85 1895.725 | 7571.2 10854.5 6894.9 10304.2 5454.1 3179.9 3431.4 2819.9 6174.5 2481.6 -3692.9 8906.2 3721.325 5184.875 | 3893.3 4182.7 3176.2 5365.8 1524 1808 1102 1757.6 2492.1 1132.9 -1359.2 4154.5 1547.9 2606.6 | 4635.3 1516.9 5390.5 4523.9 1137 1649.9 1497.5 770.6 1583.4 1678.9 95.5 4016.65 1263.75 2752.9 | 10756.1 4475.7 7375.7 4207.6 2043.6 2940 1300.5 2171.3 3573.8 1351.5 -2222.3 6703.775 2113.85 4589.925 |
| Whether meet | Not | Not | Not | Not | Not | Not | Not | Not | Be | Not |
In the table 47: the rate of not meeting is 9/10.Infer the PBMC of tested sample for the normal people.
Embodiment 48
Operation is with reference to embodiment 1, and the result is referring to table 48.
Table 48. cross validation 24-1
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T1 T2 T3 T4 N1 N2 N3 N5 T5 | 6615.2 11386.6 5944.1 5007.4 21113.1 10817.5 13886.1 17733.3 11102.05 6973.1 -4128.95 7238.325 15887.5 -8649.175 | 340.3 658.7 496.2 453.5 773 782.5 1022.6 1396.6 715.85 703.5 -12.35 487.175 993.675 -506.5 | 657.9 730.5 1018.2 890.8 2161.5 1772.8 1846.8 1949.2 1395.5 1478.2 82.7 824.35 1932.575 -1108.225 | 708.1 553.5 698.7 484.8 919.2 1117.8 1752.5 1110 813.65 673.4 -140.25 611.275 1224.875 -613.6 | 508.6 963.8 522.8 745.3 1460.3 1194.4 1253.1 1367.2 1079.1 642.2 -436.9 685.125 1318.75 -633.625 | 4103.5 2495.1 3439.2 3504.5 1374.7 2041.6 1114.9 1311.9 2268.35 2453.1 184.75 3385.575 1460.775 1924.8 | 7571.2 10854.5 6894.9 10304.2 5454.1 3179.9 2481.6 2819.9 6174.5 8012.7 1838.2 8906.2 3483.875 5422.325 | 3893.3 4182.7 3176.2 5365.8 1524 1808 1132.9 1757.6 2492.1 2728.2 236.1 4154.5 1555.625 2598.875 | 4635.3 1516.9 5390.5 4523.9 1137 1649.9 1678.9 770.6 1664.4 2784.2 1119.8 4016.65 1309.1 2707.55 | 10756.1 4475.7 7375.7 4207.6 2043.6 2940 1351.5 2171.3 3573.8 3860.3 286.5 6703.775 2126.6 4577.175 |
| Whether meet | Be | Be | Not | Be | Be | Be | Be | Be | Be | Be |
In the table 48: coincidence rate is 9/10.Infer that tested sample is carcinoma of the pancreas patient's PBMC.
Embodiment 49
Operation is with reference to embodiment 1, and the result is referring to table 49.
Table 49. cross validation 24-2
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| The training group | T1 T2 T3 T4 N1 N2 N3 N5 | 6615.2 11386.6 5944.1 5007.4 21113.1 10817.5 13886.1 17733.3 | 340.3 658.7 496.2 453.5 773 782.5 1022.6 1396.6 | 657.9 730.5 1018.2 890.8 2161.5 1772.8 1846.8 1949.2 | 708.1 553.5 698.7 484.8 919.2 1117.8 1752.5 1110 | 508.6 963.8 522.8 745.3 1460.3 1194.4 1253.1 1367.2 | 4103.5 2495.1 3439.2 3504.5 1374.7 2041.6 1114.9 1311.9 | 7571.2 10854.5 6894.9 10304.2 5454.1 3179.9 2481.6 2819.9 | 3893.3 4182.7 3176.2 5365.8 1524 1808 1132.9 1757.6 | 4635.3 1516.9 5390.5 4523.9 1137 1649.9 1678.9 770.6 | 10756.1 4475.7 7375.7 4207.6 2043.6 2940 1351.5 2171.3 |
| The median test group differs from 1 T mean N difference in means 2 | N4 | 11102.05 16847.6 5745.55 7238.325 15887.5 -8649.175 | 715.85 1836.3 1120.45 487.175 993.675 -506.5 | 1395.5 2274.3 878.8 824.35 1932.575 -1108.225 | 813.65 1455 641.35 611.275 1224.875 613.6 | 1079.1 1472.4 393.3 685.125 1318.75 -633.625 | 2268.35 1231.2 -1037.15 3385.575 1460.775 1924.8 | 6174.5 3431.4 -2743.1 8906.2 3483.875 5422.325 | 2492.1 1102 -1390.1 4154.5 1555.625 2598.875 | 1664.4 1497.5 -166.9 4016.65 1309.1 2707.55 | 3573.8 1300.5 -2273.3 6703.775 2126.6 4577.175 |
| Whether meet | Not | Not | Not | Not | Not | Not | Not | Not | Not | Not |
In the table 49: the rate of not meeting is 10/10.Infer the PBMC of tested sample for the normal people.
Embodiment 50
Operation is with reference to embodiment 1, and the result is referring to table 50.
Table 50. cross validation 25-1
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| Training group median test group differs from 1 T mean N difference in means 2 | T1 T2 T3 T4 N1 N2 N3 N4 T5 | 6615.2 11386.6 5944.1 5007.4 21113.1 10817.5 13886.1 16847.6 11102.05 6973.1 -4128.95 7238.325 15666.075 -8427.75 | 340.3 658.7 496.2 453.5 773 782.5 1022.6 1836.3 715.85 703.5 -12.35 487.175 1103.6 -616.425 | 657.9 730.5 1018.2 890.8 2161.5 1772.8 1846.8 2274.3 1395.5 1478.2 82.7 824.35 2013.85 -1189.5 | 708.1 553.5 698.7 484.8 919.2 1117.8 1752.5 1455 813.65 673.4 -140.25 611.275 1311.125 -699.85 | 508.6 963.8 522.8 745.3 1460.3 1194.4 1253.1 1472.4 1079.1 642.2 -436.9 685.125 1345.05 -659.925 | 4103.5 2495.1 3439.2 3504.5 1374.7 2041.6 1114.9 1231.2 2268.35 2453.1 184.75 3385.575 1440.6 1944.975 | 7571.2 10854.5 6894.9 10304.2 5454.1 3179.9 2481.6 3431.4 6174.5 8012.7 1838.2 8906.2 3636.75 5269.45 | 3893.3 4182.7 3176.2 5365.8 1524 1808 1132.9 1102 2492.1 2728.2 236.1 4154.5 1391.725 2762.775 | 4635.3 1516.9 5390.5 4523.9 1137 1649.9 1678.9 1497.5 1664.4 2784.2 1119.8 4016.65 1490.825 2525.825 | 10756.1 4475.7 7375.7 4207.6 2043.6 2940 1351.5 1300.5 3573.8 3860.3 286.5 6703.775 1908.9 4794.875 |
| Whether meet | Be | Be | Not | Be | Be | Be | Be | Be | Be | Be |
In the table 50: coincidence rate is 9/10.Infer that tested sample is carcinoma of the pancreas patient's PBMC.
Embodiment 51
Operation is with reference to embodiment 1, and the result is referring to table 51.
Table 51. cross validation 25-2
| Sample | L48784 | X83300 | AI620827 | AI494291 | NM_020970 | BF433657 | J02959 | BC022313 | NM_000904 | NM_004994 | |
| The training group | T1 T2 | 6615.2 11386.6 | 340.3 658.7 | 657.9 730.5 | 708.1 553.5 | 508.6 963.8 | 4103.5 2495.1 | 7571.2 10854.5 | 3893.3 4182.7 | 4635.3 1516.9 | 10756.1 4475.7 |
| The median test group differs from 1 T mean N difference in means 2 | T3 T4 N1 N2 N3 N4 N5 | 5944.1 5007.4 21113.1 10817.5 13886.1 16847.6 11102.05 17733.3 6631.25 7238.325 15666.075 -8427.75 | 496.2 453.5 773 782.5 1022.6 1836.3 715.85 1396.6 680.75 487.175 1103.6 -616.425 | 1018.2 890.8 2161.5 1772.8 1846.8 2274.3 1395.5 1949.2 553.7 824.35 2013.85 -1189.5 | 698.7 484.8 919.2 1117.8 1752.5 1455 813.65 1110 296.35 611.275 1311.125 -699.85 | 522.8 745.3 1460.3 1194.4 1253.1 1472.4 1079.1 1367.2 288.1 685.125 1345.05 -659.925 | 3439.2 3504.5 1374.7 2041.6 1114.9 1231.2 2268.35 1311.9 -956.45 3385.575 1440.6 1944.975 | 6894.9 10304.2 5454.1 3179.9 2481.6 3431.4 6174.5 2819.9 -3354.6 8906.2 3636.75 5269.45 | 3176.2 5365.8 1524 1808 1132.9 1102 2492.1 1757.6 -734.5 4154.5 1391.725 2762.775 | 5390.5 4523.9 1137 1649.9 1678.9 1497.5 1664.4 770.6 -893.8 4016.65 1490.825 2525.825 | 7375.7 4207.6 2043.6 2940 1351.5 1300.5 3573.8 2171.3 -1402.5 6703.775 1908.9 4794.875 |
| Whether meet | Not | Not | Not | Not | Not | Not | Not | Not | Not | Not |
In the table 51: the rate of not meeting is 10/10.Infer the PBMC of tested sample for the normal people.
The sequence that the present invention relates to
＜110〉Zhejiang University
＜120〉assortment of genes and the application of one group of screening ductal adenocarcinoma of pancreas
<160>10
<170>Patent In Version 2.1
<210>1
<211>220
＜213〉people
<400>1
L48784
1 gaatcagaga tcattgattt cttcctgggg gcctctctca aggatgaggt tttgaagatt
61 atgccagtgc agaagcagac ccgtgccggc cagcgcacca ggttcaaggt acccggctgt
121 cctgggaggg ggctgcgctg ggcttgccgg gactctctcg gctctgcata gttgcacttg
181 gcttcacccg tgtgactttc gtaacgggga gagagagaaa
<210>2
<211>1295
＜213〉people
<400>2
X83300
1 gtgaaagagc aggttctgct tctttggtgt agtcctgaag cttcctaaga aacttcacat
61 caggtgatgg ataggagcaa ccctgtaaaa ccagccttag actatttttc aaacaggctg
121 gtgaattacc agatctccgt caagtgcagt aaccagttca agttggaagt gtgtcttttg
181 aatgcagaaa acaaagtcgt ggacaaccag gctgggaccc agggccagct gaaggtgctg
241 ggtgccaacc tctggtggcc gtacctgatg cacgaacacc ccgcctacct gtactcgtgg
301 gaggatggtg attgctcaca ccaaagcctt ggacccctcc cagcctgtga cctttgtgac
361 caactccacc tacgcagcag acaagggggc tctgtatgtg gatgtgatcc gtgtgaacgg
421 ctactactct tggtatcgca actacgggca cctggagttg attcagctgc agctggccgc
481 ccagtttgag aattggtgta agacatcaca atcccattat tcagagcgcg tatggagtgg
541 aaacgcttgt agggtttcac caggtaagcg gtgttgaact ttctgcttgt gtattctctc
601 tgggcagaga tgccacttgc ctcccccacc atgccatctc tgaagaatat tacagaccat
661 tttggagcat ggtgaataag aaattttcac cttaggagtt cagttgaata gtcattttta
721 tatttgtgac tgcaagtcac tcttaggggc tgtacttcct tagtactggt agcattatta
781 tccaatggac ttttatagct ttcattaggt tttcttttgt ttttgttctt taaagaacgt
841 tttacttatc ttagtatttc atttttcatc tatattatga ggcagtaaga gtcttctgtt
901 tttccaaagt tgagactgct ttatatttat ttcgtattgt ctacagctgt agtgttcaat
961 acattagcca ctagccacat gtggttattt aaataagata aaataaaaat tggccgggcg
1021 tggtgggtca cgccggtaat cccagcactt tgggaggccg aggcgggcag atcattaggt
1081 caggagatcg agaccatcct tactaagacg gtgaaccccc atctctatta aaaatacaaa
1141 aaattagccg ggcgtggtgg cgggcgcctg cagtcccagc tactcaggag gctgaggcag
1201 gagaatggcg tgaacctggg aggcagagtt tgcagtgagc cgagatggcg ccactgcact
1261 ccagcctggg gacagagcga gactccatct caaaa
<210>3
<211>776
＜213〉people
<400>3
AI620827
1 ttacacttgt tagatcttta ttcattatag attctccaat gatttgcaat ggttgtagcg
61 ttactgaaga ctttgtgaca atcattacat tagtcaagtt tccctacacc atgaactgcc
121 tgatggtgaa taagtgttga ctgcttgcta aaggctttgc cacactcatt acacttgtaa
181 ggtttctctc cagtgtgaag tccagtatgt tgtttcaggt gtgaatcact cccaaaagtc
241 ttgtcacaaa ccttacattt gtatggtttc tttccaggat gaattctcct atgtctttta
301 aggtgtgatt tgcgactgaa aactttgtca catgtttcac atttgtaaag tttctcccca
361 gcatgaattc tatgatgaag tgaaagttgt gattgttgat taaaagcctt cccacattca
421 ttacacttgt aaggtttctc tgcagtgtga attctgggat gtcttgccag gtatgaatta
481 cgcacgaaag ccttgtcaca accgtacatt tgtaagattt ctctccagta tgaagtctac
541 natggtgaac caagggatgg cttggggact gaagtccttg cacactcatt acacttgtaa
601 gtttctcaac cactatgagn ctacgatgga aaggaagatg acccttggac tgaggcttgg
661 ttgactcatt taactggaag gttctaacac tatgaactct gaatggctgc aagatgacct
721 aagaacgagc ttgctgacta atacacttga agtctttccc ttgaaaacta atggtg
<210>4
<211>447
＜213〉people
<400>4
AI494291
1 ttttttttaa gaaaattcag taattctcca ttgaacatct actacatatc caactctgtg
61 ctaaggtatg ctgtggaaaa gtcaaggaag aatgtatgag acacatccct gcactcccag
121 gagtttataa tttcggagga gatgcaaacg tggacccatt ttaatgtaac aaaagataca
181 ctgtgttaac agccaaaatg gaggcctgta cagagtactg gggcaacctg gaaatctggt
241 tttaggatac actgcattca aagcaatttg cttttttctt caacatttct tgagcacctg
301 ttatgtgcaa agcaaggagt caggtgcctt tctggaaaac gaaataaaca cggcactgtc
361 tctgtttaca actgcccatt taacaaacat ttcttgaaca tctactacat gtgatgcatt
421 gagctcaacc ttaggaattg cagatgg
<210>5
<211>2418
＜213〉people
<400>5
NM_020970
1 gtgcagaaag caccgtcttt tactagaaga agacaataaa atgttggtca atgaactgaa
61 tcattcgaaa gaaaaagaat gccaatatga aaaagagaaa gcagaaagag aagtagctgt
121 gagacagctt caacaaaaac gagatgatgt cttaaacaaa ggatcagcaa caaaagctct
181 gctggatgct tcatcgcgtc actgcaccta tttagaaaat gggatgcagg attcaaggaa
241 gaaattagac cagatgagaa gtcaatttca agaaatacag gatcaactta cagctactat
301 aagatgtact aaggagatgg atggcgacac acaaaagctt gaagtagaac atgtgatgat
361 gagaaaaatt attaaaaaac aggatgacca aattgagcgg cttgagaaaa tcctgcagca
421 ttcaagtttg atgctgcagg tgtttgagag ctagatgaag atatggacat ttctggaatt
481 aagagccccc tctacattga gcacaagaca gtgacgaatc cacattcttc agccagaaag
541 tcacctctga gagccaaatg tctgactata gaaaggagag tcaaagaatg ataacgacat
601 ctcaggaaaa ttgtgaaaat aatcagcagc cggatgtgga taaccctttc aaatttctcc
661 tggggcctcc aaccaccccc actggtgttc tcctgctgac agtgatttca attttttctg
721 ggctggagct ccctgatgga ggggcaggcc accatctttg ctgtttttgc aacttagcca
781 cttcagcctt cagtctttgg agtgtccaag gagaccaggg ggtgatgtgg accctcagca
841 tagcacagct gctctataaa gatgaggcca gactgctttt ttgagcactt tcccaatgcc
901 attcctcctc actgggcaaa acctccaaac tggggtctcc agccacctcc tacaggtgtg
961 tttgggccag caacaagttc attcatacct ccctagggca aagcttccaa agggagcggt
1021 aggctgccat ctttgctgtt tcacaggctt cactgatgat aactccaggt actggaaaat
1081 ctgaggctac tagagactgg agcgggccct gggcatactg cagcagccct atggaaaagt
1141 ggccagactg ttacctgggt tcccattcct atatcttctc actaggcaag tcttgcaggc
1201 ctgggcctct acctaacccc ccctaccaga actgttgagc cagtagcaac tcagccactc
1261 cctggagaga gcctccaggg gcaactgaaa gcctctctgc cactgcttct gcagtggaac
1321 tgtccttgct accctcagac tgatgaagga gctaacaccc ttatctacac cttcaacaag
1381 ctttaattga ccaaagccca tctctcatgg gttctacaca ctccccactg ctcatgacag
1441 ggaacccctg gattggcccc cacagcacga attctccatc ctgattgctg attgcagtaa
1501 acagttgctg tattctccag gggtggtgga actctgagga gacaaacaaa agacccttgg
1561 ctacaaccac tactaatgtc ccttcctctt ctgcctcaaa gttaggaaag aaatataaac
1621 actgagattg ccccagagct gcagtgggca gcctaggagt gccaagccat gacctacagc
1681 cagcactcaa gggggagaga agcacatttt cagatcattg agagggaaca tggctgcaac
1741 tgtaaggaaa cataggggag ccacatgacc aagcaagagt ctaccaactg accagtaagc
1801 ccaagtgcca cctactggat cacatcccaa agcttcagca tcaaaaatac cctactaata
1861 tactcccctc tgaaaccaga aatgagaagt cagcttcaaa taaagaccct gcacaaagcc
1921 tcagcctggt gaaaacatcc gaaaataagt ctacggactg tactcaatct acactgcaat
1981 taaaggaaaa cccataggtg gaaatgagaa gaaaccaatg caagaactcc agtaactcaa
2041 atggcctctg tgtcatatgt ccttctaaca accacaccag ttctccaaca agagttctta
2101 acctggatga actgtctgga attacataaa tataattcag aatatggata ggaaaaaaaa
2161 tcatcaagac tcaggagaat ggcaaaaccc aatccaagga aaataagaat aacagtaaag
2221 tgttacagga gctgaaggat aaagtagctg gtataataaa aaagaaccta accgatctga
2281 aagcgccgaa gaacacaata caagaattcc acaatgcaat cacaagtatt aacagcagaa
2341 aaaaaaacct gaggaacgaa tctcagaact tgaagattgg ttctctaaaa taagatggac
2401 aaaaaaaaaa aaaaaaaa
<210>6
<211>549
＜213〉people
<400>6
BF433657
1 ttttttgttt tcccttgact ttatttatct tcataagtca caaaatgtga gtgcagagat
61 aaatgtctgt gtgcatgtgc cctgagcaca cagggtggca taactcggca cactcataat
121 gacacagccg ttcacccagc cacagatagt gacagggcac acatggcgac acccacatgt
181 acggagataa atctccccca ccatgacatg ggtagacaga aaacacgccg cagtatactc
241 tagtatgttt acacaaacag ggagacaggc ccgtgcaatg catgtcacca acacccacac
301 tcagagtgac atctgctgga ggtgctcaga cacagccacc caccgtgaca tgccgagact
361 cacatatgtc acatgacaca ggcatgcatg ccacattcac tgtgactctc agtcctattc
421 attcatcacc tttctgggag atacactgaa atgtccaccc tttgcaaaat gcacacacac
481 gcgcacgcac acacgcacac acacgaacac acgcgcacac acgcacacac acgcacgcag
541 gtgtacaca
<210>7
<211>1910
＜213〉people
<400>7
J02959
1 gggcgctgtg ctgtgtgatc ccccagagcc atgcccgaga tagtggatac ctgttcgttg
61 gcctctccgg cttccgtctg ccggaccaag cacctgcacc tgcgctgcag cgtcgacttt
121 actcgccgga cgctgaccgg gactgctgct ctcacggtcc agtctcagga ggacaatctg
181 cgcagcctgg ttttggatac aaaggacctt acaatagaaa aagtagtgat caatggacaa
241 gaagtcaaat atgctcttgg agaaagacaa agttacaagg gatcgccaat ggaaatctct
301 cttcctatcg ctttgagcaa aaatcaagaa attgttatag aaatttcttt tgagacctct
361 ccaaaatctt ctgctctcca gtggctcact cctgaacaga cttctgggaa ggaacaccca
421 tatctcttta gtcagtgcca ggccatccac tgcagagcaa tccttccttg tcaggacact
481 ccttctgtga aattaaccta tactgcagag gtgtctgtcc ctaaagaact ggtggcactt
541 atgagtgcta ttcgtgatgg agaaacacct gacccagaag acccaagcag gaaaatatac
601 aaattcatcc aaaaagttcc aataccctgc tacctgattg ctttagttgt tggagcttta
661 gaaagcaggc aaattggccc aagaactttg gtgtggtctg agaaagagca ggtggaaaag
721 tctgcttatg agttttctga gactgaatct atgcttaaaa tagcagaaga tctgggagga
781 ccgtatgtat ggggacagta tgacctattg gtcctgccac catccttccc ttatggtggc
841 atggagaatc cttgccttac ttttgtaact cctactctac tggcaggcga caagtcactc
901 tccaatgtca ttgcacatga aatatctcat agctggacag ggaatctagt gaccaacaaa
961 acttgggatc acttttggtt aaatgaggga catactgtgt acttggaacg ccacatttgc
1021 ggacgattgt ttggtgaaaa gttcagacat tttaatgctc tgggaggatg gggagaacta
1081 cagaattcgg taaagacatt tggggagaca catcctttca ccaaacttgt ggttgatctg
1141 acagatatag accctgatgt agcttattct tcagttccct atgagaaggg ctttgcttta
1201 cttttttacc ttgaacaact gcttggagga ccagagattt tcctaggatt cttaaaagct
1261 tatgttgaga agttttccta taagagcata actactgatg actggaagga tttcctgtat
1321 tcctatttta aagataaggt tgatgttctc aatcaagttg attggaatgc ctggctctac
1381 tctcctggac tgcctcccat aaagcccaat tatgatatga ctctgacaaa tgcttgtatt
1441 gccttaagtc aaagatggat tactgccaaa gaagatgatt taaattcatt caatgccaca
1501 gacctgaagg atctctcttc tcatcaattg aatgagtttt tagcacagac gctccagagg
1561 gcacctcttc cattggggca cataaagcga atgcaagagg tgtacaactt caatgccatt
1621 aacaattctg aaatacgatt cagatggctg cggctctgca ttcaatccaa gtgggaggac
1681 gcaattcctt tggcgctaaa gatggcaact gaacaaggaa gaatgaagtt tacccggccc
1741 ttattcaagg atcttgctgc ctttgacaaa tcccatgatc aagctgtccg aacctaccaa
1801 gagcacaaag caagcatgca tcccgtgact gcaatgctgg tggggaaaga cttaaaagtg
1861 gattaaagac ctgcgtattg atgattttag agatttctct tttttaaatg
<210>8
<211>1154
＜213〉people
<400>8
BC022313
1 aatcaagaag ttggcgtgca gctgggagag ctagactaag ttggtcatga tgcagaagct
61 actcaaatgc agtcggcttg tcctggctct tgccctcatc ctggttctgg aatcctcagt
121 tcaaggtaag actcaggagt cttgttcccc agccatcttc tctgtaagcc ctgtggtcca
181 tgcaagtcat tatattcatt ttaaggcata gaatgtataa tattgtgaga aaggaggcaa
241 agaagaagga tttggggtcg ctgaaccctt taatatgagt tctgttaagt ttggtaccaa
301 gaaaaattaa actctgtggc gtgtgcagtc ttgtaaactc ttacaatgat tgaaatgtgc
361 tattttggga tgaaaatgtg aggtttataa attttaaaag ctcaaaaaag gaatctagaa
421 aatgactcct gtgcctgttg catggaggag atggcacctt tgactgttgg ggggtgtctg
481 cctaccccta agtgtctaca tcagccccaa gttttagtgc gctgtgacgg tgtcattgtt
541 attttaacac tgggagacgt tatattccaa ttggggtgaa tctgactgtg tgtattttct
601 tttctttttt tttttttaaa gataaacttg gttcttactg aaaactcaat tatggttaga
661 catagttcat gtaaaacctc tcagatttta aagagaaggc caaataattt ggtatttgtg
721 ctcttgctca gagaagcatc atattcggaa atatcttcct aggtttatct accatttagt
781 gttgtttagt cagactgaaa caacttaaaa cctgtaatga ctaagacaat gaaaatgata
841 ggcttgtaag aaaaatacaa tttgttattc tttggcaaat aaggaatcat gtctaaataa
901 gacggaggtc atggcttgat agagagatgg ctgaacctat agtagaaaaa cactaggttc
961 cgccaaatgg taagggaaat gttgagtcac aatgacacac atgtcctaga tttgtttcgt
1021 caaagcgact tttggttgtc atgatcttac ttccggtgga ggttgcagtg agctgagatc
1081 atgccattgc actccaggct aggcaacaga gtgcaactcc gtcccaaaaa aaaaaaaaaa
1141 aaaaaaaaaa aaaa
<210>9
<211>976
＜213〉people
<400>9
NM_000904
1 cccggaacct ggcgcaactc ctagagcggt ccttggggag acgcgggtcc cagtcctgcg
61 gctcctactg gggagtgcgc tggtcggaag attgctggac tcgctgaaga gagactacgc
121 aggaaagccc cagccaccca tcaaatcaga gagaaggaat ccaccttctt acgctatggc
181 aggtaagaaa gtactcattg tctatgcaca ccaggaaccc aagtctttca acggatcctt
241 gaagaatgtg gctgtagatg aactgagcag gcagggctgc accgtcacag tgtctgattt
301 gtatgccatg aactttgagc cgagggccac agacaaagat atcactggta ctctttctaa
361 tcctgaggtt ttcaattatg gagtggaaac ccacgaagcc tacaagcaaa ggtctctggc
421 tagcgacatc actgatgagc agaaaaaggt tcgggaggct gacctagtga tatttcagtt
481 cccgctgtac tggttcagcg tgccggccat cctgaagggc tggatggata gggtgctgtg
541 ccagggcttt gcctttgaca tcccaggatt ctacgattcc ggtttgctcc agggtaaact
601 agcgctcctt tccgtaacca cgggaggcac ggccgagatg tacacgaaga caggagtcaa
661 tggagattct cgatacttcc tgtggccact ccagcatggc acattacact tctgtggatt
721 taaagtcctt gcccctcaga tcagctttgc tcctgaaatt gcatccgaag aagaaagaaa
781 ggggatggtg gctgcgtggt cccagaggct gcagaccatc tggaaggaag agcccatccc
841 ctgcacagcc cactggcact tcgggcaata actctgtggc acgtgggcat cacgtaagca
901 gcacactagg aggcccaggc gcaggcaaag agaagatggt gctgtcatga aataaaatta
961 caacatagct acctgg
<210>10
<211>2387
＜213〉people
<400>10
NM_004994
1 agacacctct gccctcacca tgagcctctg gcagcccctg gtcctggtgc tcctggtgct
61 gggctgctgc tttgctgccc ccagacagcg ccagtccacc cttgtgctct tccctggaga
121 cctgagaacc aatctcaccg acaggcagct ggcagaggaa tacctgtacc gctatggtta
181 cactcgggtg gcagagatgc gtggagagtc gaaatctctg gggcctgcgc tgctgcttct
241 ccagaagcaa ctgtccctgc ccgagaccgg tgagctggat agcgccacgc tgaaggccat
301 gcgaacccca cggtgcgggg tcccagacct gggcagattc caaacctttg agggcgacct
361 caagtggcac caccacaaca tcacctattg gatccaaaac tactcggaag acttgccgcg
421 ggcggtgatt gacgacgcct ttgcccgcgc cttcgcactg tggagcgcgg tgacgccgct
481 caccttcact cgcgtgtaca gccgggacgc agacatcgtc atccagtttg gtgtcgcgga
541 gcacggagac gggtatccct tcgacgggaa ggacgggctc ctggcacacg cctttcctcc
601 tggccccggc attcagggag acgcccattt cgacgatgac gagttgtggt ccctgggcaa
661 gggcgtcgtg gttccaactc ggtttggaaa cgcagatggc gcggcctgcc acttcccctt
721 catcttcgag ggccgctcct actctgcctg caccaccgac ggtcgctccg acggcttgcc
781 ctggtgcagt accacggcca actacgacac cgacgaccgg tttggcttct gccccagcga
841 gagactctac acccaggacg gcaatgctga tgggaaaccc tgccagtttc cattcatctt
901 ccaaggccaa tcctactccg cctgcaccac ggacggtcgc tccgacggct accgctggtg
961 cgccaccacc gccaactacg accgggacaa gctcttcggc ttctgcccga cccgagctga
1021 ctcgacggtg atggggggca actcggcggg ggagctgtgc gtcttcccct tcactttcct
1081 gggtaaggag tactcgacct gtaccagcga gggccgcgga gatgggcgcc tctggtgcgc
1141 taccacctcg aactttgaca gcgacaagaa gtggggcttc tgcccggacc aaggatacag
1201 tttgttcctc gtggcggcgc atgagttcgg ccacgcgctg ggcttagatc attcctcagt
1261 gccggaggcg ctcatgtacc ctatgtaccg cttcactgag gggcccccct tgcataagga
1321 cgacgtgaat ggcatccggc acctctatgg tcctcgccct gaacctgagc cacggcctcc
1381 aaccaccacc acaccgcagc ccacggctcc cccgacggtc tgccccaccg gaccccccac
1441 tgtccacccc tcagagcgcc ccacagctgg ccccacaggt cccccctcag ctggccccac
1501 aggtcccccc actgctggcc cttctacggc cactactgtg cctttgagtc cggtggacga
1561 tgcctgcaac gtgaacatct tcgacgccat cgcggagatt gggaaccagc tgtatttgtt
1621 caaggatggg aagtactggc gattctctga gggcaggggg agccggccgc agggcccctt
1681 ccttatcgcc gacaagtggc ccgcgctgcc ccgcaagctg gactcggtct ttgaggagcg
1741 gctctccaag aagcttttct tcttctctgg gcgccaggtg tgggtgtaca caggcgcgtc
1801 ggtgctgggc ccgaggcgtc tggacaagct gggcctggga gccgacgtgg cccaggtgac
1861 cggggccctc cggagtggca gggggaagat gctgctgttc agcgggcggc gcctctggag
1921 gttcgacgtg aaggcgcaga tggtggatcc ccggagcgcc agcgaggtgg accggatgtt
1981 ccccggggtg cctttggaca cgcacgacgt cttccagtac cgagagaaag cctatttctg
2041 ccaggaccgc ttctactggc gcgtgagttc ccggagtgag ttgaaccagg tggaccaagt
2101 gggctacgtg acctatgaca tcctgcagtg ccctgaggac tagggctccc gtcctgcttt
2161 ggcagtgcca tgtaaatccc cactgggacc aaccctgggg aaggagccag tttgccggat
2221 acaaactggt attctgttct ggaggaaagg gaggagtgga ggtgggctgg gccctctctt
2281 ctcacctttg ttttttgttg gagtgtttct aataaacttg gattctctaa cctttaaaaa
2341 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaa
Claims (3)
1. the assortment of genes of one group of screening ductal adenocarcinoma of pancreas, it is characterized in that:, have the gene order of SEQ ID NO:1～SEQ ID NO:10 respectively by L48784, X83300, AI620827, AI494291, NM_020970, BF433657, J02959, BC022313, ten assortments of genes of NM_000904, NM_004994.
2. the application of the assortment of genes of one group of screening ductal adenocarcinoma of pancreas according to claim 1 in the screening ductal adenocarcinoma of pancreas.
3. the application of the assortment of genes of one group of screening ductal adenocarcinoma of pancreas according to claim 2 in the screening ductal adenocarcinoma of pancreas is achieved through the following technical solutions:
(1) sets up screening criteria: according to Affymetrix chip gene expression profile operational guidance, use AFFYMETRIX HUMAN GENOME U133 PLUS 2.0 ARRAY to detect this expression of group gene in 5 Pancreas cancer patients and 5 normal peoples' peripheral blood mononuclear cell, obtain the signal value of genetic expression;
The gene that the average signal value of (2) 5 Pancreas cancer patients peripheral blood mononuclear cell is higher than 5 normal peoples is considered to the up-regulated expression gene; The gene that the average signal value of 5 Pancreas cancer patients is lower than 5 normal peoples is considered to reduce expressing gene;
(3) median of getting genetic expression signal value in above-mentioned 10 peripheral blood mononuclear cell is as threshold value, is to raise or downward modulation is expressed with the genetic expression of the peripheral blood mononuclear cell of judging tested person; The people's of tested person peripheral blood mononuclear cell, the expression trend that has the expression conditions more than 7 or 7 to raise in the carcinoma of the pancreas peripheral blood mononuclear cell or reduce with these genes in 10 genes is consistent, and just predicts the artificial carcinoma of the pancreas patient of tested person; If the people's of tested person peripheral blood mononuclear cell, the expression trend that has expression conditions more than 7 or 7 and these genes to raise in carcinoma of the pancreas or reduce in 10 genes does not meet, and the people who just predicts tested person is the normal people.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100526794A CN1904072B (en) | 2006-07-28 | 2006-07-28 | Gene composition for screening pancreatic catheter gland cancer and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100526794A CN1904072B (en) | 2006-07-28 | 2006-07-28 | Gene composition for screening pancreatic catheter gland cancer and its application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1904072A true CN1904072A (en) | 2007-01-31 |
| CN1904072B CN1904072B (en) | 2012-07-18 |
Family
ID=37673435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006100526794A Expired - Fee Related CN1904072B (en) | 2006-07-28 | 2006-07-28 | Gene composition for screening pancreatic catheter gland cancer and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1904072B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2320443T3 (en) * | 2002-09-30 | 2009-05-22 | Oncotherapy Science, Inc. | GENES AND POLYPEPTIDES RELATED TO HUMAN PANCREATIC CANCERS. |
-
2006
- 2006-07-28 CN CN2006100526794A patent/CN1904072B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1904072B (en) | 2012-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1156587C (en) | Chinese dendrobe plant and its medicinal materials DNA molecular diagnosis method | |
| CN1497049A (en) | Androgen receptor compound-associated protein | |
| CN1934261A (en) | Oxidation by hydrogen peroxide | |
| CN1877328A (en) | Method for detecting aquatic animal pathogenic bacteria by using 23S ribosome gene probe array | |
| CN101045945A (en) | Gene chip for detecting several kinds of common pathogenic bacteria and its prepn process and kit | |
| CN101067149A (en) | CYP3A detecting chip and its application | |
| CN101045944A (en) | Gene chip for detecting six kinds of diarrhea pathogens and its prepn process and kit | |
| CN1633500A (en) | Primers for nucleic acid amplification in detecting housekeeping gene mRNA and test method using these primers | |
| CN1697883A (en) | Method of detecting target nucleotide sequence, detection target structure to be used in embodying the method, process for producing the same and assay kit for detecting target nucleotide sequence | |
| CN1160459C (en) | Cytochrome BD type quinol oxidase gene of brevibacterium lactofermentum | |
| CN1778930A (en) | Fusion gene of provocative organ anti-Coccidium tenellum infection and its coding protein and use thereof | |
| CN1173989C (en) | DNA sequence of dendrobium and method for discriminating its veriety and judging if it is true or false | |
| CN1693481A (en) | Customized micro-array construction and its use for target molecule detection | |
| CN1904072A (en) | Gene composition for screening pancreatic catheter gland cancer and its application | |
| CN1771337A (en) | A plynucleotide associated with a colon cancer comprising single nucleotide polymorphism, microarray and diagnostic kit comprising the same and method for diagnosing a colon cancer using the polynucle | |
| CN1526111A (en) | Polymorphic marker that can be used to assess the efficacy of interferon therapy | |
| CN1969044A (en) | DNA array and method of detecting single nucleotide polymorphism | |
| CN1782096A (en) | PNA chip using ZIP code and method for preparing the same | |
| CN1891718A (en) | Fusion immunotoxin ML-L-SEC2 and gene and its preparation | |
| CN1169969C (en) | RET oligo-nucleotide microchip and method for detecting genetic cancer | |
| CN1255186C (en) | New use of gens mutant of human telomerase inverse transcriptase-like component | |
| CN1763106A (en) | A kind of antiviral fusion protein and encoding gene thereof and application | |
| CN1517710A (en) | Beta-interlink protein oligonucleotide microchip and method for testing beta-interlink protein mutation by it | |
| CN100342035C (en) | Method for testing receptor mutation of epidermkal growth factor in lung adenocarcinoma of non-smoker | |
| CN1800390A (en) | Genes relating to arising and development of oral squamous cell carcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120718 Termination date: 20130728 |